
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Randomized adaptive assessment of post COVID syndrome treatments (RAPID): a study protocol for a multicenter, randomized, controlled adaptive platform trial of treatment options for Post Covid Syndrome (PCS) on patients physical function including the first intervention specific appendix RAPID_REVIVE (reducing inflammatory activity in patients with PCS) - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E4B6338AF3B9B305B633002D342114.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="trials">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366011/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Trials">
<meta name="citation_title" content="Randomized adaptive assessment of post COVID syndrome treatments (RAPID): a study protocol for a multicenter, randomized, controlled adaptive platform trial of treatment options for Post Covid Syndrome (PCS) on patients physical function including the first intervention specific appendix RAPID_REVIVE (reducing inflammatory activity in patients with PCS)">
<meta name="citation_author" content="Lisa Weipert">
<meta name="citation_author_institution" content="Department II of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany">
<meta name="citation_author" content="Ralph G Telgmann">
<meta name="citation_author_institution" content="Clinical Trials Unit, University Medical Center Göttingen, Göttingen, Germany">
<meta name="citation_author" content="Gabriele Anton">
<meta name="citation_author_institution" content="Medical School OWL, Bielefeld University, Bielefeld, Germany">
<meta name="citation_author" content="Thomas Asendorf">
<meta name="citation_author_institution" content="Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany">
<meta name="citation_author" content="Irina Chaplinskaja-Sobol">
<meta name="citation_author_institution" content="University Medical Center Göttingen, Department of Medical Informatics, Göttingen, Germany">
<meta name="citation_author" content="Sandra Ciesek">
<meta name="citation_author_institution" content="Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany">
<meta name="citation_author" content="Oliver A Cornely">
<meta name="citation_author_institution" content="University of Cologne, Faculty of Medicine, University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECA), Cologne, Germany">
<meta name="citation_author_institution" content="University of Cologne, Faculty of Medicine, University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany">
<meta name="citation_author_institution" content="German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany">
<meta name="citation_author_institution" content="University of Cologne, Faculty of Medicine, University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany">
<meta name="citation_author" content="Sonja Drescher">
<meta name="citation_author_institution" content="Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany">
<meta name="citation_author" content="Carsten Finke">
<meta name="citation_author_institution" content="Department of Neurology, Charité, University Medicine Berlin, Berlin, Germany, Berlin School of Mind and Brain, Humboldt-Universität zu Berlin, Berlin, Germany">
<meta name="citation_author" content="Tim Friede">
<meta name="citation_author_institution" content="Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany">
<meta name="citation_author" content="Julia Groth">
<meta name="citation_author_institution" content="Helmholtz Centre Munich, Institute of Epidemiology, Department of Molecular Epidemiology, Munich, Germany">
<meta name="citation_author" content="Sabine Hanß">
<meta name="citation_author_institution" content="University Medical Center Göttingen, Department of Medical Informatics, Göttingen, Germany">
<meta name="citation_author" content="Wolfgang Hoffmann">
<meta name="citation_author_institution" content="Institute of Community Medicine, Department of Healthcare Epidemiology and Community Health, University Medicine Greifswald, Greifswald, Germany">
<meta name="citation_author" content="Cynthia Huber">
<meta name="citation_author_institution" content="Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany">
<meta name="citation_author" content="Thomas Illig">
<meta name="citation_author_institution" content="Hannover Medical School, Hannover Unified Biobank, Hannover, Germany">
<meta name="citation_author" content="Monika Kraus">
<meta name="citation_author_institution" content="Helmholtz Centre Munich, Institute of Epidemiology, Department of Molecular Epidemiology, Munich, Germany">
<meta name="citation_author" content="Dagmar Krefting">
<meta name="citation_author_institution" content="University Medical Center Göttingen, Department of Medical Informatics, Göttingen, Germany">
<meta name="citation_author" content="Sebastian Kuhn">
<meta name="citation_author_institution" content="Institute for Digital Medicine, University Hospital Giessen-Marburg, Philipps University Marburg, Marburg, Germany">
<meta name="citation_author" content="Andreas Muehler">
<meta name="citation_author_institution" content="Immunic AG, Lochhamer Schlag 21, Gräfelfing, 82166 Germany">
<meta name="citation_author" content="Matthias Nauck">
<meta name="citation_author_institution" content="Institute for Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany">
<meta name="citation_author" content="Jens Schaller">
<meta name="citation_author_institution" content="Institute for Cardiovascular Computer-Assisted Medicine, Charité, University Medicine Berlin, Berlin, Germany">
<meta name="citation_author" content="Ann-Cathrin Schmidt">
<meta name="citation_author_institution" content="Department II of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany">
<meta name="citation_author" content="Georg Schmidt">
<meta name="citation_author_institution" content="Klinikum rechts der Isar, Technical University of Munich, Munich, Germany">
<meta name="citation_author" content="Birgit Sawitzki">
<meta name="citation_author_institution" content="Institute of Medical Immunology, Charité, University Medicine Berlin, Berlin, Germany">
<meta name="citation_author" content="Ralf Tostmann">
<meta name="citation_author_institution" content="Clinical Trials Unit, University Medical Center Göttingen, Göttingen, Germany">
<meta name="citation_author" content="Heike Valentin">
<meta name="citation_author_institution" content="Institute of Community Medicine, Department of Healthcare Epidemiology and Community Health, University Medicine Greifswald, Greifswald, Germany">
<meta name="citation_author" content="Maria Vehreschild">
<meta name="citation_author_institution" content="Department II of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany">
<meta name="citation_publication_date" content="2025 Aug 19">
<meta name="citation_volume" content="26">
<meta name="citation_firstpage" content="297">
<meta name="citation_doi" content="10.1186/s13063-025-09008-0">
<meta name="citation_pmid" content="40830806">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366011/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366011/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366011/pdf/13063_2025_Article_9008.pdf">
<meta name="description" content="The majority of patients recovers from severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) coronavirus disease 2019 (COVID-19) without obvious sequelae, but a significant proportion suffers long-term consequences which have been termed ...">
<meta name="og:title" content="Randomized adaptive assessment of post COVID syndrome treatments (RAPID): a study protocol for a multicenter, randomized, controlled adaptive platform trial of treatment options for Post Covid Syndrome (PCS) on patients physical function including the first intervention specific appendix RAPID_REVIVE (reducing inflammatory activity in patients with PCS)">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="The majority of patients recovers from severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) coronavirus disease 2019 (COVID-19) without obvious sequelae, but a significant proportion suffers long-term consequences which have been termed ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366011/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12366011">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s13063-025-09008-0"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/13063_2025_Article_9008.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12366011%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12366011/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12366011/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366011/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-trials.png" alt="Trials logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Trials" title="Link to Trials" shape="default" href="https://trialsjournal.biomedcentral.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Trials</button></div>. 2025 Aug 19;26:297. doi: <a href="https://doi.org/10.1186/s13063-025-09008-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s13063-025-09008-0</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22Trials%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Trials%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Trials%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Trials%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Randomized adaptive assessment of post COVID syndrome treatments (RAPID): a study protocol for a multicenter, randomized, controlled adaptive platform trial of treatment options for Post Covid Syndrome (PCS) on patients physical function including the first intervention specific appendix RAPID_REVIVE (reducing inflammatory activity in patients with PCS)</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Weipert%20L%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Lisa Weipert</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Lisa Weipert</span></h3>
<div class="p">
<sup>1</sup>Department II of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Weipert%20L%22%5BAuthor%5D" class="usa-link"><span class="name western">Lisa Weipert</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Telgmann%20RG%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Ralph G Telgmann</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Ralph G Telgmann</span></h3>
<div class="p">
<sup>2</sup>Clinical Trials Unit, University Medical Center Göttingen, Göttingen, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Telgmann%20RG%22%5BAuthor%5D" class="usa-link"><span class="name western">Ralph G Telgmann</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Anton%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Gabriele Anton</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Gabriele Anton</span></h3>
<div class="p">
<sup>3</sup>Medical School OWL, Bielefeld University, Bielefeld, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Anton%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Gabriele Anton</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Asendorf%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Thomas Asendorf</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Thomas Asendorf</span></h3>
<div class="p">
<sup>4</sup>Department of Medical Statistics,  University Medical Center Göttingen, Göttingen, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Asendorf%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Thomas Asendorf</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chaplinskaja-Sobol%20I%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Irina Chaplinskaja-Sobol</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Irina Chaplinskaja-Sobol</span></h3>
<div class="p">
<sup>5</sup>University Medical Center Göttingen, Department of Medical Informatics, Göttingen, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chaplinskaja-Sobol%20I%22%5BAuthor%5D" class="usa-link"><span class="name western">Irina Chaplinskaja-Sobol</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ciesek%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Sandra Ciesek</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Sandra Ciesek</span></h3>
<div class="p">
<sup>6</sup> Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ciesek%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sandra Ciesek</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cornely%20OA%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Oliver A Cornely</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Oliver A Cornely</span></h3>
<div class="p">
<sup>7</sup>University of Cologne, Faculty of Medicine, University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECA), Cologne, Germany </div>
<div class="p">
<sup>18</sup>University of Cologne, Faculty of Medicine, University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany </div>
<div class="p">
<sup>19</sup>German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany </div>
<div class="p">
<sup>20</sup>University of Cologne, Faculty of Medicine, University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Cornely%20OA%22%5BAuthor%5D" class="usa-link"><span class="name western">Oliver A Cornely</span></a>
</div>
</div>
<sup>7,</sup><sup>18,</sup><sup>19,</sup><sup>20</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Drescher%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Sonja Drescher</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Sonja Drescher</span></h3>
<div class="p">
<sup>4</sup>Department of Medical Statistics,  University Medical Center Göttingen, Göttingen, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Drescher%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sonja Drescher</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Finke%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Carsten Finke</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Carsten Finke</span></h3>
<div class="p">
<sup>8</sup>Department of Neurology, Charité,  University Medicine Berlin, Berlin, Germany, Berlin School of Mind and Brain, Humboldt-Universität zu Berlin, Berlin, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Finke%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Carsten Finke</span></a>
</div>
</div>
<sup>8</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Friede%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Tim Friede</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Tim Friede</span></h3>
<div class="p">
<sup>4</sup>Department of Medical Statistics,  University Medical Center Göttingen, Göttingen, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Friede%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Tim Friede</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Groth%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id11"><span class="name western"> Julia Groth</span></a><div hidden="hidden" id="id11">
<h3><span class="name western"> Julia Groth</span></h3>
<div class="p">
<sup>11</sup>Helmholtz Centre Munich, Institute of Epidemiology, Department of Molecular Epidemiology, Munich, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Groth%20J%22%5BAuthor%5D" class="usa-link"><span class="name western"> Julia Groth</span></a>
</div>
</div>
<sup>11</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Han%C3%9F%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id12"><span class="name western">Sabine Hanß</span></a><div hidden="hidden" id="id12">
<h3><span class="name western">Sabine Hanß</span></h3>
<div class="p">
<sup>5</sup>University Medical Center Göttingen, Department of Medical Informatics, Göttingen, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Han%C3%9F%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Sabine Hanß</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hoffmann%20W%22%5BAuthor%5D" class="usa-link" aria-describedby="id13"><span class="name western">Wolfgang Hoffmann</span></a><div hidden="hidden" id="id13">
<h3><span class="name western">Wolfgang Hoffmann</span></h3>
<div class="p">
<sup>9</sup>Institute of Community Medicine, Department of Healthcare Epidemiology and Community Health, University Medicine Greifswald, Greifswald, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hoffmann%20W%22%5BAuthor%5D" class="usa-link"><span class="name western">Wolfgang Hoffmann</span></a>
</div>
</div>
<sup>9</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huber%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id14"><span class="name western">Cynthia Huber</span></a><div hidden="hidden" id="id14">
<h3><span class="name western">Cynthia Huber</span></h3>
<div class="p">
<sup>4</sup>Department of Medical Statistics,  University Medical Center Göttingen, Göttingen, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huber%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Cynthia Huber</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Illig%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id15"><span class="name western">Thomas Illig</span></a><div hidden="hidden" id="id15">
<h3><span class="name western">Thomas Illig</span></h3>
<div class="p">
<sup>10</sup>Hannover Medical School, Hannover Unified Biobank, Hannover, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Illig%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Thomas Illig</span></a>
</div>
</div>
<sup>10</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kraus%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id16"><span class="name western">Monika Kraus</span></a><div hidden="hidden" id="id16">
<h3><span class="name western">Monika Kraus</span></h3>
<div class="p">
<sup>11</sup>Helmholtz Centre Munich, Institute of Epidemiology, Department of Molecular Epidemiology, Munich, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kraus%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Monika Kraus</span></a>
</div>
</div>
<sup>11</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Krefting%20D%22%5BAuthor%5D" class="usa-link" aria-describedby="id17"><span class="name western">Dagmar Krefting</span></a><div hidden="hidden" id="id17">
<h3><span class="name western">Dagmar Krefting</span></h3>
<div class="p">
<sup>5</sup>University Medical Center Göttingen, Department of Medical Informatics, Göttingen, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Krefting%20D%22%5BAuthor%5D" class="usa-link"><span class="name western">Dagmar Krefting</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kuhn%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id18"><span class="name western"> Sebastian Kuhn</span></a><div hidden="hidden" id="id18">
<h3><span class="name western"> Sebastian Kuhn</span></h3>
<div class="p">
<sup>12</sup>Institute for Digital Medicine, University Hospital Giessen-Marburg, Philipps University Marburg, Marburg, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kuhn%20S%22%5BAuthor%5D" class="usa-link"><span class="name western"> Sebastian Kuhn</span></a>
</div>
</div>
<sup>12</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Muehler%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id19"><span class="name western">Andreas Muehler</span></a><div hidden="hidden" id="id19">
<h3><span class="name western">Andreas Muehler</span></h3>
<div class="p">
<sup>13</sup>Immunic AG, Lochhamer Schlag 21, Gräfelfing, 82166 Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Muehler%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Andreas Muehler</span></a>
</div>
</div>
<sup>13</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nauck%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id20"><span class="name western">Matthias Nauck</span></a><div hidden="hidden" id="id20">
<h3><span class="name western">Matthias Nauck</span></h3>
<div class="p">
<sup>14</sup>Institute for Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Nauck%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Matthias Nauck</span></a>
</div>
</div>
<sup>14</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Schaller%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id21"><span class="name western">Jens Schaller</span></a><div hidden="hidden" id="id21">
<h3><span class="name western">Jens Schaller</span></h3>
<div class="p">
<sup>15</sup>Institute for Cardiovascular Computer-Assisted Medicine,  Charité, University Medicine Berlin, Berlin, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Schaller%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jens Schaller</span></a>
</div>
</div>
<sup>15</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Schmidt%20AC%22%5BAuthor%5D" class="usa-link" aria-describedby="id22"><span class="name western">Ann-Cathrin Schmidt</span></a><div hidden="hidden" id="id22">
<h3><span class="name western">Ann-Cathrin Schmidt</span></h3>
<div class="p">
<sup>1</sup>Department II of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Schmidt%20AC%22%5BAuthor%5D" class="usa-link"><span class="name western">Ann-Cathrin Schmidt</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Schmidt%20G%22%5BAuthor%5D" class="usa-link" aria-describedby="id23"><span class="name western">Georg Schmidt</span></a><div hidden="hidden" id="id23">
<h3><span class="name western">Georg Schmidt</span></h3>
<div class="p">
<sup>16</sup>Klinikum rechts der Isar, Technical University of Munich,  Munich, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Schmidt%20G%22%5BAuthor%5D" class="usa-link"><span class="name western">Georg Schmidt</span></a>
</div>
</div>
<sup>16</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sawitzki%20B%22%5BAuthor%5D" class="usa-link" aria-describedby="id24"><span class="name western">Birgit Sawitzki</span></a><div hidden="hidden" id="id24">
<h3><span class="name western">Birgit Sawitzki</span></h3>
<div class="p">
<sup>17</sup>Institute of Medical Immunology, Charité, University Medicine Berlin, Berlin, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Sawitzki%20B%22%5BAuthor%5D" class="usa-link"><span class="name western">Birgit Sawitzki</span></a>
</div>
</div>
<sup>17</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tostmann%20R%22%5BAuthor%5D" class="usa-link" aria-describedby="id25"><span class="name western">Ralf Tostmann</span></a><div hidden="hidden" id="id25">
<h3><span class="name western">Ralf Tostmann</span></h3>
<div class="p">
<sup>2</sup>Clinical Trials Unit, University Medical Center Göttingen, Göttingen, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Tostmann%20R%22%5BAuthor%5D" class="usa-link"><span class="name western">Ralf Tostmann</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Valentin%20H%22%5BAuthor%5D" class="usa-link" aria-describedby="id26"><span class="name western">Heike Valentin</span></a><div hidden="hidden" id="id26">
<h3><span class="name western">Heike Valentin</span></h3>
<div class="p">
<sup>9</sup>Institute of Community Medicine, Department of Healthcare Epidemiology and Community Health, University Medicine Greifswald, Greifswald, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Valentin%20H%22%5BAuthor%5D" class="usa-link"><span class="name western">Heike Valentin</span></a>
</div>
</div>
<sup>9</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vehreschild%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id27"><span class="name western">Maria Vehreschild</span></a><div hidden="hidden" id="id27">
<h3><span class="name western">Maria Vehreschild</span></h3>
<div class="p">
<sup>1</sup>Department II of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Vehreschild%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Maria Vehreschild</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Department II of Internal Medicine, Infectious Diseases, Goethe University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany </div>
<div id="Aff2">
<sup>2</sup>Clinical Trials Unit, University Medical Center Göttingen, Göttingen, Germany </div>
<div id="Aff3">
<sup>3</sup>Medical School OWL, Bielefeld University, Bielefeld, Germany </div>
<div id="Aff4">
<sup>4</sup>Department of Medical Statistics,  University Medical Center Göttingen, Göttingen, Germany </div>
<div id="Aff5">
<sup>5</sup>University Medical Center Göttingen, Department of Medical Informatics, Göttingen, Germany </div>
<div id="Aff6">
<sup>6</sup> Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany </div>
<div id="Aff7">
<sup>7</sup>University of Cologne, Faculty of Medicine, University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECA), Cologne, Germany </div>
<div id="Aff8">
<sup>8</sup>Department of Neurology, Charité,  University Medicine Berlin, Berlin, Germany, Berlin School of Mind and Brain, Humboldt-Universität zu Berlin, Berlin, Germany </div>
<div id="Aff9">
<sup>9</sup>Institute of Community Medicine, Department of Healthcare Epidemiology and Community Health, University Medicine Greifswald, Greifswald, Germany </div>
<div id="Aff10">
<sup>10</sup>Hannover Medical School, Hannover Unified Biobank, Hannover, Germany </div>
<div id="Aff11">
<sup>11</sup>Helmholtz Centre Munich, Institute of Epidemiology, Department of Molecular Epidemiology, Munich, Germany </div>
<div id="Aff12">
<sup>12</sup>Institute for Digital Medicine, University Hospital Giessen-Marburg, Philipps University Marburg, Marburg, Germany </div>
<div id="Aff13">
<sup>13</sup>Immunic AG, Lochhamer Schlag 21, Gräfelfing, 82166 Germany </div>
<div id="Aff14">
<sup>14</sup>Institute for Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany </div>
<div id="Aff15">
<sup>15</sup>Institute for Cardiovascular Computer-Assisted Medicine,  Charité, University Medicine Berlin, Berlin, Germany </div>
<div id="Aff16">
<sup>16</sup>Klinikum rechts der Isar, Technical University of Munich,  Munich, Germany </div>
<div id="Aff17">
<sup>17</sup>Institute of Medical Immunology, Charité, University Medicine Berlin, Berlin, Germany </div>
<div id="Aff18">
<sup>18</sup>University of Cologne, Faculty of Medicine, University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany </div>
<div id="Aff19">
<sup>19</sup>German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany </div>
<div id="Aff20">
<sup>20</sup>University of Cologne, Faculty of Medicine, University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Feb 4; Accepted 2025 Jul 25; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12366011  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40830806/" class="usa-link">40830806</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background</h3>
<p id="Par1">The majority of patients recovers from severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) coronavirus disease 2019 (COVID-19) without obvious sequelae, but a significant proportion suffers long-term consequences which have been termed post COVID syndrome (PCS). Despite a wide range of considerations on treatment options in PCS and a significant number of trials initiated, only very few results from randomized controlled trials are currently available. In conclusion, there is an evident medical need to identify treatments for patients with PCS.</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods</h3>
<p id="Par2">The primary objective of the platform trial RAPID is to assess the impact of different PCS treatments on the overall physical function of patients. Designed as a master protocol, RAPID contains all information that is generic to this adaptive platform trial. Current and future study treatments are specified in intervention-specific appendices (ISA). The first ISA, RAPID_REVIVE is presented in this manuscript. General sections of the master protocol are named as such.</p>
<p id="Par3">RAPID_REVIVE is a double-blind, placebo-controlled, phase II clinical trial evaluating antiviral PCS treatment with vidofludimus calcium (IMU-838). Patients are randomized at a 1:1 ratio to 45 mg/day vidofludimus calcium (22.5 mg for the first 7 days) or placebo during an initialization phase and thereafter using a response-adaptive randomization procedure. The trial includes a screening period of 7 days, a double-blind treatment period of 56 days and a follow-up period of 28 days. The primary outcome is the intra-patient change in physical function measured by the Short Form-36 Physical Function (SF-36-PF) from baseline to day 56. Secondary endpoints include mental and physical health, intensity of fatigue, severity of mental disorder symptoms, and cognitive function.</p></section><section id="sec3"><h3 class="pmc_sec_title">Discussion</h3>
<p id="Par4">PCS is a major problem for global health care and the identification of treatment options is urgently needed. Currently, PCS patients are in a situation without evidence-based treatment options, and quality of life, and often mental health are significantly impaired. The purpose of RAPID is to establish an adaptive platform trial protocol which will concert and quicken clinical trials to evaluate the efficacy and safety of different potential treatments for PCS with the aim to expand the very limited evidence base for the treatment of PCS.</p></section><section id="sec4"><h3 class="pmc_sec_title">Trial registration</h3>
<p id="Par5">EU Clinical Trials Register (CTIS) ID: 2024–511628-16–00 (RAPID_REVIVE). Registered on 18.03.2024.</p></section><section id="sec5"><h3 class="pmc_sec_title">Supplementary Information</h3>
<p>The online version contains supplementary material available at 10.1186/s13063-025-09008-0.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Post COVID syndrome, Adaptive Platform Study, Vidofludimus calcium, Physical function, Fatigue, Cognitive function</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Administrative information</h2>
<p id="Par77">Note: the numbers in curly brackets in this protocol refer to SPIRIT checklist item numbers. The order of the items has been modified to group similar items (see <a href="http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/</a>).
</p>
<section class="tw xbox font-sm" id="Taba"><div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups"><tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Title {1}</td>
<td align="left" colspan="1" rowspan="1">Randomized adaptive Assessment of Post COVID syndrome treatments (RAPID), A Multicenter, Randomized, Controlled Adaptive Platform Study on the Safety and Efficacy of Investigational Therapeutics and Interventions for the treatment of Post Covid Syndrome (PCS) with one intervention specific subprotocol RAPID_REVIVE</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Trial registration {2a and 2b}.</td>
<td align="left" colspan="1" rowspan="1">EU Clinical Trials Register (CTIS) ID: 2024–511628-16–00 (RAPID_REVIVE), date of registration: 18–03-24</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Protocol version {3}</td>
<td align="left" colspan="1" rowspan="1">V 2.0, 13.05.2024</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Funding {4}</td>
<td align="left" colspan="1" rowspan="1">This publication was funded by the German Federal Ministry of Education and Research (BMBF) Network of University Medicine 2.0: “NUM 2.0", Grant No. 01KX2121, Projects: NAPKON-TIP and NAPKON-TIP: RAPID trial</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Author details {5a}</td>
<td align="left" colspan="1" rowspan="1">
<p>Lisa Weipert<sup>1</sup>, Ralph G. Telgmann<sup>2</sup>, Gabriele Anton<sup>3</sup>, Thomas Asendorf<sup>4</sup>, Irina Chaplinskaja-Sobol<sup>5</sup>, Sandra Ciesek<sup>6</sup>, Oliver A. Cornely<sup>7</sup>, Sonja Drescher<sup>4</sup>, Carsten Finke<sup>8</sup>, Tim Friede<sup>4</sup>, Julia Groth<sup>11</sup>, Sabine Hanß<sup>5</sup>, Wolfgang Hoffmann<sup>9</sup>, Cynthia Huber<sup>4</sup>, Thomas Illig<sup>10</sup>, Monika Kraus<sup>11</sup>, Dagmar Krefting<sup>5</sup>, Sebastian Kuhn<sup>12</sup>, Andreas Muehler<sup>13</sup>, Matthias Nauck<sup>14</sup>, Jens Schaller<sup>15</sup>, Ann-Cathrin Schmidt<sup>1</sup>, Georg Schmidt<sup>16</sup>, Birgit Sawitzki<sup>17</sup>, Ralf Tostmann<sup>2</sup>, Heike Valentin<sup>9</sup>, Maria Vehreschild<sup>1</sup></p>
<p><sup>1</sup>Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany</p>
<p><sup>2</sup>Clinical Trials Unit, University Medical Center Göttingen, Göttingen, Germany</p>
<p><sup>3</sup>Medical School OWL, Bielefeld University, Bielefeld, Germany</p>
<p><sup>4</sup>Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany</p>
<p><sup>5</sup>University Medical Center Göttingen, Department of Medical Informatics, Göttingen, Germany</p>
<p><sup>6</sup>Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany</p>
<p><sup>7</sup>University of Cologne, Faculty of Medicine, University Hospital Cologne, Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany</p>
<p>University of Cologne, Faculty of Medicine, University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany</p>
<p>German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany</p>
<p>University of Cologne, Faculty of Medicine, University Hospital Cologne, Clinical Trials Centre Cologne (ZKS Köln), Cologne, Germany</p>
<p><sup>8</sup>Department of Neurology, Charité, University Medicine Berlin, Berlin, Germany, Berlin School of Mind and Brain, Humboldt-Universität zu Berlin, Berlin, Germany</p>
<p><sup>9</sup>Institute of Community Medicine, Department of Healthcare Epidemiology and Community Health, University Medicine Greifswald, Greifswald, Germany</p>
<p><sup>10</sup>Hannover Medical School, Hannover Unified Biobank, Hannover, Germany</p>
<p><sup>11</sup>Helmholtz Centre Munich, Institute of Epidemiology, Department of Molecular Epidemiology, Munich, Germany</p>
<p><sup>12</sup>Institute for Digital Medicine, University Hospital Giessen-Marburg, Philipps University Marburg, Marburg, Germany.</p>
<p><sup>13</sup>Immunic AG, Lochhamer Schlag 21, 82,166 Gräfelfing, Germany</p>
<p><sup>14</sup>Institute for Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany</p>
<p><sup>15</sup>Institute for Cardiovascular Computer-Assisted Medicine, Charité, University Medicine Berlin, Berlin, Germany</p>
<p><sup>16</sup>Klinikum rechts der Isar, Technical University of Munich, Munich, Germany</p>
<p><sup>17</sup>Institute of Medical Immunology, Charité, University Medicine Berlin, Berlin, Germany</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Name and contact information for the trial sponsor {5b}</td>
<td align="left" colspan="1" rowspan="1">
<p>Goethe University Frankfurt represented by</p>
<p>Prof. Dr. med. Maria J.G.T. Vehreschild</p>
<p>University Hospital Frankfurt</p>
<p>Innere Medizin II, Infektiologie</p>
<p>Theodor-Stern-Kai 7</p>
<p>60,590 Frankfurt, Germany.</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Role of sponsor {5c}</td>
<td align="left" colspan="1" rowspan="1">The funder BMBF did not influence the study design and will not influence the collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication.</td>
</tr>
</tbody></table></div>
<div class="p text-right font-secondary"><a href="table/Taba/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="Sec2"><h2 class="pmc_sec_title">Introduction</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Background and rationale {6a}</h3>
<section id="Sec4"><h4 class="pmc_sec_title">Post COVID syndrome</h4>
<p id="Par78">The majority of patients recover from severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) coronavirus disease 2019 (COVID-19) without obvious sequelae, but a significant proportion suffers long-term consequences which have been termed post COVID syndrome (PCS) [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>–<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>]. About 10–20% of patients who experienced COVID-19 report persistent or new symptoms, according to the World Health Organization (WHO), which is a major problem for global health care [<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>, <a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>]. The diverse clinical symptoms may be explained by the broad expression of the angiotensin converting enzyme 2 receptor (ACE2). This receptor is required by SARS-CoV-2 to enter the cell and is ubiquitously expressed in many tissues (lung, kidney, small intestine, olfactory neuroepithelium, heart, testis, “substantia nigra,” and muscle cells) [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>, <a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>]. The presence of ACE2 receptors in the vascular endothelium and the gut, as well as the occurrence of accompanying inflammatory and immunological processes provide a hypothesis potentially explaining the high diversity of clinical manifestations of COVID-19. These include fatigue, muscle pain, dyspnea, headache, olfactory/gustatory dysfunction, cognitive dysfunction (attentional and executive impairments), depression, and anxiety [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>, <a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>–<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>]. In a significant number of cases, the above-described signs and symptoms persist over longperiods and potentially life-long.</p></section><section id="Sec5"><h4 class="pmc_sec_title">Rationale for adaptive platform trial</h4>
<p id="Par79">Despite a wide range of considerations on treatment options in PCS and a significant number of trials initiated, only very few results from randomized controlled trials are currently available. At the same time, numerous hypotheses concerning potentially effective treatment strategies are slowly emerging from ongoing research [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>]. This adaptive platform study evaluates the efficacy and safety of several different potential treatments which are being developed for post COVID syndrome (PCS). The platform study design enables multiple study interventions to be evaluated in a clinical study in a simultaneous manner. Platform study designs have specific operating characteristics which need to be carefully considered and balanced against the complexity which is introduced. For this study, the design is anticipated to provide a more efficient means of evaluating novel therapies for the treatment of PCS. The first intervention-specific appendix (ISA) RAPID_REVIVE (Reducing Inflammatory Activity in Patients with PCS syndrome) of the overarching master protocol RAPID (Randomized adaptive Assessment of Post COVID syndrome treatments) is presented here in this manuscript. Generic sections of the master protocol are named as such.</p></section><section id="Sec6"><h4 class="pmc_sec_title">Rationale of RAPID_REVIVE</h4>
<p id="Par80">An increased level of inflammatory activity has been shown to play a key role in the pathogenesis and chronic clinical picture of PCS. There are, however, multiple factors that have been hypothesized to trigger aberrant inflammatory activation [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>]. These include, among others, two potentially relevant causes of PCS and thus suitable treatment targets, persistence of SARS-CoV-2 for &gt; 6 months after COVID-19, as well as reactivation of Epstein-Barr virus (EBV) and other dormant viruses [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>, <a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. In detail, persistent “spike 1” (S1) protein could be found in CD16 + monocytes from PCS patients [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>], and the intestine has been shown to harbor SARS-CoV-2 long after a COVID-19 infection [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>, <a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>]. Furthermore, patients receiving antiviral treatment for their acute COVID-19 disease have been shown to experience PCS less frequently and/or severely than untreated patients [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>–<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. In a case series, in which individuals were treated with Nirmatrelvir/Ritonavir at various stages following infection, improvement of PCS symptoms was shown [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. This argues for the SARS-CoV-2 reservoir being an important determinant in causing persistent inflammation as a pathogenetic factor in PCS. Besides persistence of SARS-CoV-2 itself, the reactivation of other latent viral infections, e.g., EBV may be associated with PCS. In line with this hypothesis, there is an increasing number of studies reporting virus reactivation including EBV in patients with PCS. Depending on the study, EBV reactivation was observed in 50–95% of patients, indicated by anti-EBV-antibodies or EBV viremia [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>, <a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>–<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>]. Virus reactivation may occur as early as 2 weeks of SARS-CoV-2 infection [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. EBV reactivation was also associated with fatigue in hospitalized and non-hospitalized patients [<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>]. Besides viral persistence and reactivation, other factors may also contribute to the onset of PCS. Initial exposure to SARS-CoV-2 may set off a cascade of autoimmune responses. Such initial inflammatory activation may be reinforced through the presence of a disbalanced gut microbiota or a procoagulatory response of the coagulation cascade [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>]. Concerning the need for identification of treatment targets for PCS, RAPID_REVIVE focuses on addressing the pathomechanisms associated with viral persistence and reactivation to improve clinical signs and symptoms of PCS.</p></section><section id="Sec7"><h4 class="pmc_sec_title">IMU-838</h4>
<p id="Par81">Vidofludimus calcium (IMU-838) is a small molecule that selectively inhibits the enzyme dihydroorotate dehydrogenase (DHODH), which catalyzes the rate-limiting step of the de novo pyrimidine synthesis. It represents a novel chemical class with no structural similarity to other known, commercially available DHODH inhibitors (i.e., leflunomide, teriflunomide) [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>]. IMU-838 specifically affects pyrimidine synthesis in cells with exceptionally high need for nucleotides, while other host cells can cover their requirement for pyrimidines via salvage pathways. Cell types in high need of pyrimidine include cancer and virus-infected cells, but also hyperactive cells in chronic inflammatory diseases [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. In the latter, inhibiting DHODH causes secondary metabolic stress that leads to a reduction of pro-inflammatory cytokine release. Moreover, activation of metabolic stress pathways results in the induction of an IFN-independent innate immune response. Thereby, IMU-838 prevents viral replication directly by diminishing the cellular pyrimidine pool and indirectly by an IFN-independent upregulation of IFN-stimulated genes with antiviral activity [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. Of note, the antiviral effect of DHODH inhibition is independent of virus-specific proteins and their structure. Thus, IMU-838 exhibits a broad-spectrum antiviral activity against different viruses (including SARS-CoV-2 variants, EBV, hepatitis C virus, human immunodeficiency virus (HIV-1), human cytomegalovirus, and influenza A virus) with an antiviral efficacy in the low micromolar range in vitro [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>]. IMU-838 was selected for this trial based on existing clinical and safety data in COVID-19 patients, as well as its broad antiviral spectrum. In a phase 2 trial of IMU-838, 223 hospitalized COVID-19 patients were randomized to standard-of-care plus either placebo (<em>n</em> = 112) or IMU-838 45 mg (<em>n</em> = 111). Data received from this trial indicate a shorter time to clinical improvement after treatment with IMU-838 and a correlation between IMU-838 trough levels and the number of days to clinical recovery [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>]. Furthermore, results from a post hoc analysis of PCS symptoms indicated a potential contribution of IMU-838 to the prevention of long-term fatigue, one of the most common post COVID-19 symptoms. At initial clinical and viral remission from the SARS-CoV-2 infection, 80% patients who received placebo reported fatigue compared to 50% patients receiving IMU-838 45 mg. Fatigue decreased in both treatment groups in the following 9–17 weeks to 33% in placebo and 17% in IMU-838 recipients. In the same trial, IMU-838 treatment in COVID-19 patients was found to be well tolerated [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>]. Premature study discontinuations for any reason or related to study treatment were similar between IMU-838 and placebo. Likewise, rates of treatment emergent adverse events (AEs) of grade 3 or higher and serious adverse events (SAEs) were low and comparable between IMU-838 and placebo. In conclusion, IMU-838 potentially acts on three potential underlying causes of PCS, namely persistence of a SARS- CoV-2 reservoir, reactivation of latent viral infections, and chronic upregulation of inflammation. Concerning the approach of using antiviral treatments to treat PCS, several trials with an intention to assess the use of 10 days nirmatrelvir have been registered (<a href="https://clinicaltrials.gov/ct2/show/NCT05595369" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05595369</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT05576662" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05576662</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT05823896" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05823896</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT05852873" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05852873</a>), but no trial assessing the efficacy of IMU-838 in this indication has been set up so far, despite its multiple potential mechanisms of action against PCS. The first ISA of the RAPID adaptive platform trial (APT) will fill this gap. IMU-838 does not only display activity against SARS-CoV-2, but also against other viruses (e.g., EBV, cytomegalovirus (CMV)) that may reactivate in the context of COVID 19 and thus initiate PCS [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>].</p></section></section><section id="Sec8"><h3 class="pmc_sec_title">Objectives {7}</h3>
<p id="Par82">The primary generic objective of the RAPID platform trial is to compare the impact of the individual PCS treatment to control on patient overall physical function as measured by the Short Form-36 Physical Function (SF-36-PF) from baseline to day 56 in adults with PCS. While this primary objective also applies to each ISA, secondary objectives are specified for each ISA.</p>
<p id="Par83">Secondary objectives of the ISA RAPID_REVIVE that is presented in this manuscript are to compare the impact of PCS treatment with IMU-838 to control on patient overall mental and physical health at days 28, 56, and 84, to compare the impact of PCS treatment with IMU-838 to control on patient- and physician-reported outcomes measuring key PCS neuropsychiatric symptoms, on patient- and physician-reported outcomes measuring key physical PCS symptoms and on autonomic function and physical activity parameters. With the objective to identify and preselect patients that might benefit from the selected intervention, blood, fecal, and imaging biomarkers will be evaluated as exploratory endpoints. The safety objective is to evaluate safety and tolerability of IMU-838 (see Table <a href="#Tab2" class="usa-link">2</a>).</p>
<section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>Objectives and related endpoints</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Objective</th>
<th align="left" colspan="1" rowspan="1">Endpoint</th>
</tr></thead>
<tbody>
<tr><td align="left" colspan="2" rowspan="1">RAPID</td></tr>
<tr><td align="left" colspan="2" rowspan="1">Primary</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Compare the impact of PCS treatment to control on patient overall physical function</td>
<td align="left" colspan="1" rowspan="1">Intra-patient change in physical function as measured by the Short Form-36 Physical Function (SF-36-PF)</td>
</tr>
<tr><td align="left" colspan="2" rowspan="1">Secondary</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Compare the impact of PCS treatment on secondary objecttives specified by ISA</td>
<td align="left" colspan="1" rowspan="1">Intra-patient change in parameter specified by ISA</td>
</tr>
<tr><td align="left" colspan="2" rowspan="1">Safety</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  To evaluate safety and tolerability of treatment</td>
<td align="left" colspan="1" rowspan="1">Type, frequency, and severity of AEs and SAEs</td>
</tr>
<tr><td align="left" colspan="2" rowspan="1">RAPID_REVIVE</td></tr>
<tr><td align="left" colspan="2" rowspan="1">Primary</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Compare the impact of PCS treatment with IMU-838 to control on patient overall physical function at day 56</td>
<td align="left" colspan="1" rowspan="1">Intra-patient change in physical function as measured by the Short Form-36 Physical Function (SF-36-PF) from baseline to day 56</td>
</tr>
<tr><td align="left" colspan="2" rowspan="1">Secondary</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Compare the impact of PCS treatment with IMU-838 to control on patient overall mental and physical health at days 28, 56, and 84</td>
<td align="left" colspan="1" rowspan="1">Intra-patient change in overall mental and physical health as measured by the SF-36-PF; from baseline to days 28, 56, and 84</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Compare the impact of PCS treatment with IMU-838 to control on patient- and physician-reported outcomes measuring key PCS neuropsychiatric symptoms</td>
<td align="left" colspan="1" rowspan="1">
<p>Intra-patient change from baseline to days 28, 56, and 84 in</p>
<p>- Intensity of fatigue and incapacitation measured by the FSS</p>
<p>- Severity of mental disorder symptoms such as depression, anxiety, somatization, and distress measured by the PHQ modules PHQ-9, PHQ-15, and PHQ-stress and GAD-7</p>
<p>Intra-patient change from baseline to days 28 and 56 in</p>
<p>- Cognitive function measured by the MoCa</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Compare the impact of PCS treatment with IMU-838 to control on patient- and physician-reported outcomes measuring key physical PCS symptoms</td>
<td align="left" colspan="1" rowspan="1">
<p>Intra-patient change from baseline to days 28, 56, and 84 in</p>
<p>- Severity of dyspnea, measured by the mMRC</p>
<p>- PEM frequency, strength and severity as measured by the PEM questionnaire</p>
<p>Intra-patient change from baseline to days 28 and 56 in</p>
<p>- Orthostatic/autonomic dysfunction measured by the PST</p>
<p>- Physical exercise capacity, measured as the change in number of repetitions during the 1-min sit-to-stand test (1MSTST)</p>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Compare the impact of PCS treatment with IMU-838 to control on autonomic function and physical activity parameters</td>
<td align="left" colspan="1" rowspan="1">
<p>Intra-patient change from baseline to days 28 and 56 in</p>
<p>- Physical activity parameters: global activity (steps/24 h), wear time (min), time spent in physical activity (min), resting (bpm) and activity heart rate (bpm)</p>
<p>- Autonomic function parameters: heart rate turbulence, nocturnal heart rate, nocturnal respiratory rate, expiration-triggered sinus arrhythmia, baroreflex sensitivity, frequency of spontaneous ectopic beats</p>
<p>measured by use of mhealth devices (c-med alpha, CE medical device, Cosinuss GmbH, Munich, Germany, and SaniQ, CE medical device, Qurasoft GmbH, Koblenz, Germany)</p>
</td>
</tr>
<tr><td align="left" colspan="2" rowspan="1">Exploratory</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  Identification of biomarkers to identify and pre-select patients who could benefit from the intervention</td>
<td align="left" colspan="1" rowspan="1">
<p>Blood, fecal biomarkers, and</p>
<p>Imaging biomarkers</p>
</td>
</tr>
<tr><td align="left" colspan="2" rowspan="1">Safety</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  To evaluate safety and tolerability of IMU-838</td>
<td align="left" colspan="1" rowspan="1">Type, frequency and severity of AEs and SAEs from day 1 to day 84</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p150"><p><em>1MSTST</em> 1-min sit-to-stand test, <em>cMRI</em> cerebral magnetic resonance imaging, <em>FSS</em> Fatigue Severity Scale, <em>GAD-7</em> Generalized Anxiety Disorder Scale, <em>mMRC</em> modified Medical Research Council Dyspnea Scale, <em>MoCA</em> Montreal-Cognitive-Assessment, <em>PEM</em> post exertional malaise, <em>PHQ</em> patient health questionnaire, <em>PROM</em> patient-reported outcome measures, <em>PST</em> passive standing test, <em>(S)AE</em> (serious) adverse event, <em>SF-36-PF</em> Short Form-36 Physical Function, <em>IMU-838</em> vidofludimus calcium</p></div></div></section></section></section><section id="Sec9"><h2 class="pmc_sec_title">Methods: participants, interventions and outcomes</h2>
<section id="Sec10"><h3 class="pmc_sec_title">Trial design {8}</h3>
<p id="Par84">RAPID is designed as an open end APT with the option of adding and removing interventional arms. The master protocol contains generic information like, i.e., eligibility criteria, randomization rules, endpoints, and the overarching statistical approach. The specific trial domains of care and their interventions are defined in their corresponding appendices.</p>
<p id="Par85">RAPID_REVIVE is an intervention-specific appendix (ISA) linked to the master protocol RAPID targeting treatment of PCS. RAPID_REVIVE is a phase 2 randomized, multi-center, placebo-controlled, double-blind, parallel group, superiority clinical trial with two arms. Patients are randomized 1:1 to receive either IMU-838 45 mg/day (22.5 mg/day initiation dose) or placebo for 56 days in a double-blind fashion during an initialization phase and thereafter using a response-adaptive randomization procedure. They are followed up until day 84. A flowchart of the trial is presented in Fig. <a href="#Fig1" class="usa-link">1</a>.</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366011_13063_2025_9008_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c1f/12366011/fa5c378a14d7/13063_2025_9008_Fig1_HTML.jpg" loading="lazy" id="MO1" height="293" width="777" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Trial flowchart of RAPID_REVIVE from Screening to follow up. RDZ = randomization; SOT = start of treatment; MOT = middle of treatment; EOT = end of treatment; EOS = end of study; Devices = Measurement of autonomic function and physical activity parameters by medical devices (see {18a}); Initial Treatment = 7-day initiation phase with 22.5 mg/day IMU-838; Main Treatment = 45-day treatment phase with 45 mg/day IMU-838</p></figcaption></figure></section><section id="Sec11"><h3 class="pmc_sec_title">Study setting {9}</h3>
<p id="Par86">Patients are recruited from 11 hospitals across Germany. If necessary, additional qualified sites can be included during trial conduct. All trial sites participated in patient recruitment for the 3 NAPKON (Nationales Pandemie Kohorten Netz) cohorts and benefit from the already established, central trial infrastructures. The aim of NAPKON was to recruit a high-quality cohort of patients with coronavirus disease 2019 (COVID-19) for in-depth phenotyping of the disease. NAPKON recruited all patient types and at all healthcare facilities in Germany as part of the three cohorts SÜP (Sektorenübergreifende Plattform), HAP (Hochauflösende Plattform), and POP (Populationsbasierte Plattform). The project also included the creation of infrastructures for the collection, management and provision of data, image data, and biosamples. A current list of study sites is published online on the RAPID_REVIVE website (<a href="https://www.netzwerk-universitaetsmedizin.de/projekte/napkon-tip/studie-rapid-revive" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.netzwerk-universitaetsmedizin.de/projekte/napkon-tip/studie-rapid-revive</a>).</p></section><section id="Sec12"><h3 class="pmc_sec_title">Eligibility criteria {10}</h3>
<section id="Sec13"><h4 class="pmc_sec_title">Inclusion criteria</h4>
<p id="Par87">Patients eligible for inclusion in RAPID_REVIVE must meet <em>all</em> of the following criteria (criteria 1, 2, 5, and 6 are generic to RAPID):</p>
<ol class="list" style="list-style-type:decimal">
<li><p id="Par88">Male or female patients ≥ 18 years of age</p></li>
<li><p id="Par89">Symptoms consistent with PCS that began within 4 weeks of the index infection and persisted for &gt; 12 weeks. The identified symptoms of PCS cannot be attributed to other intervening diagnoses or medications and did not exist prior to the acute COVID preceding PCS.</p></li>
<li><p id="Par90">Moderate to severe overall disability, defined as a Bell Scale [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>] of 20–60</p></li>
<li><div class="p" id="Par91"> ≥ 2 of the following post-COVID symptoms, defined as:<ol class="list" style="list-style-type:lower-alpha">
<li><div class="p" id="Par92">Fatigue, defined as an FSS score ≥ 36</div></li>
<li><div class="p" id="Par93">Cognitive impairment, defined as a MoCA score between 10 and 25</div></li>
<li><div class="p" id="Par94">Shortness of breath, defined as a mMRC ≥ 2</div></li>
<li><div class="p" id="Par95">Orthostatic/autonomic dysfunction, defined as the following results in the PST:<ul class="list" style="list-style-type:none">
<li>
<span class="label">i.</span><div class="display-inline p" id="Par96">A sustained heart rate increase of ≥ 30 bpm within 10 min. of standing or and/or a heart rate reaching &gt; 120 bpm within 10 min. of standing <em>and</em>
</div>
</li>
<li>
<span class="label">ii.</span><div class="display-inline p" id="Par97">Absence of a sustained 20 mmHg decrease in systolic blood pressure within 10 min of standing</div>
</li>
</ul>
</div></li>
</ol>
</div></li>
<li><p id="Par98">Written informed consent obtained according to international guidelines and local laws</p></li>
<li><p id="Par99">Ability to understand the nature of the trial and the trial-related procedures and to comply with them</p></li>
<li><p id="Par100">Ability to provide and use a smartphone, tablet, or other device for download and installation of the medical device software used in the trial</p></li>
<li><p id="Par101">Willingness to not connect medical devices used in this trial to any other app that is not defined in this protocol, especially not to Garmin Connect</p></li>
<li><p id="Par102">Willingness to abstain from changes in the type, dosage, and frequency of concomitant medications through day 84</p></li>
<li><p id="Par103">Use of a highly effective method of contraception correctly and consistently, as applicable, during trial treatment and for 28 days after the final dose (applicable to individuals of childbearing potential and participating men whose partners may become pregnant)</p></li>
<li><p id="Par104">Female patients of childbearing potential, must have a negative pregnancy test (at Screening-V1 (blood test; see Table <a href="#Tab1" class="usa-link">1</a>) and before the first Investigational Medicinal Product (IMP) intake (day 1 blood or urine test) AND agreement of not to attempt to become pregnant AND agreement of not to donate ova AND usage of highly effective forms of birth control (as defined by Recommendations related to contraception and pregnancy testing in clinical trials- Heads of Medicines Agencies (HMA) [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>]).</p></li>
<li><div class="p" id="Par105">Male patients must agree not to father a child or to donate sperm starting at Screening-V1, throughout the clinical study, and for 30 days after the last intake of the IMP. Male patients must also:<ol class="list" style="list-style-type:lower-alpha">
<li><div class="p" id="Par106">Abstain from sexual intercourse with a female partner (acceptable only if it is the patient’s usual form of birth control/lifestyle choice), or</div></li>
<li><div class="p" id="Par107">Use adequate barrier contraception during treatment with the IMP and until at least 30 days after the last intake of the IMP, and</div></li>
<li><div class="p" id="Par108">If they have a female partner of childbearing potential, the partner should use a highly effective contraceptive method as outlined above</div></li>
<li><div class="p" id="Par109">If they have a pregnant partner, they must use condoms while taking the IMP to avoid exposure of the fetus to the IMP.</div></li>
</ol>
</div></li>
</ol>
<section class="tw xbox font-sm" id="Tab1"><h5 class="obj_head">Table 1.</h5>
<div class="caption p"><p>Restricted medications recommended based on previous studies on IMU-838 interaction potential with drug-metabolizing enzymes and transporters</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Class or type</th>
<th align="left" colspan="1" rowspan="1">Medication/patient population</th>
<th align="left" colspan="1" rowspan="1">Reason</th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">CYP2C8 strong inducers</td>
<td align="left" colspan="1" rowspan="1">Rifampicin, barbiturates (e.g., phenobarbital), carbamazepine, ritonavir</td>
<td align="left" colspan="1" rowspan="1">Potentially decrease exposure to IMU-838 and may thus decrease efficacy</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CYP2C8 strong inhibitors</td>
<td align="left" colspan="1" rowspan="1">Gemfibrozil, clopidogrel</td>
<td align="left" colspan="1" rowspan="1">Potentially increase exposure to IMU-838 and may thus increase the risk for AEs; however uncertain due to alternative metabolic pathways of IMU-838</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">BCRP substrates with a narrow therapeutic window</td>
<td align="left" colspan="1" rowspan="1">Rosuvastatin (maximum dose: 10 mg/day), methotrexate (maximum dose: 17.5 mg/week), mitoxantrone, sulfasalazine, topotecan, daunorubicin, doxorubicin, warfarin</td>
<td align="left" colspan="1" rowspan="1">IMU-838 may inhibit transport of BCRP substrates and lead to increased exposure in plasma and/or hepatocytes and thus increased risk for substrate’s side-effects</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">BCRP strong inducers</td>
<td align="left" colspan="1" rowspan="1">DMARDs such as methotrexate (maximum dose: 17.5 mg/week), sulfasalazine</td>
<td align="left" colspan="1" rowspan="1">Potentially decrease exposure to IMU-838 and may thus decrease efficacy</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">BCRP strong inhibitors</td>
<td align="left" colspan="1" rowspan="1">Immunosuppressants (cyclosporine A, tacrolimus, sirolimus), azole antifungals (ketoconazole, itraconazole, fluconazole), proton pump inhibitors (omeprazole, pantoprazole), NSAIDs (ibuprofen, naproxen, salicylates)</td>
<td align="left" colspan="1" rowspan="1">Potentially increase exposure to IMU-838 and may thus increase the risk for AEs</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">UGT1A1 inhibitors</td>
<td align="left" colspan="1" rowspan="1">Atazanavir, canagliflozin, pazopanib, regorafenib, sorafenib, tocilizumab, tranilast</td>
<td align="left" colspan="1" rowspan="1">Combination therapy of IMU-838 and other UGT1A1 inhibitors may lead to disturbance of the bilirubin metabolism and subsequently to hyperbilirubinemia</td>
</tr>
<tr><td align="left" colspan="3" rowspan="1">Other safety precautions/restrictions for patient population related to DDI potential</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1">  UGT1A1</td>
<td align="left" colspan="1" rowspan="1">Patients with reduced UGT1A1 activity (e.g., Gilbert’s syndrome) to be excluded from clinical studies with IMU-838</td>
<td align="left" colspan="1" rowspan="1">
<p>In patients with reduced UGT1A1 activity:</p>
<p>Risk of hyperbilirubinemia</p>
</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p72"><p>Abbreviations: <em>AE</em> adverse events, <em>BCRP</em> breast cancer resistance protein, <em>CYP</em> cytochrome, <em>DDI</em> drug-drug interaction, <em>DMARDs</em> disease-modifying anti-rheumatic drugs, <em>UGT1A1</em> uridine-diphosphate glucuronosyltransferase 1A1</p></div></div></section></section></section><section id="Sec14"><h3 class="pmc_sec_title">Exclusion criteria</h3>
<p id="Par110">Patients eligible for RAPID_REVIVE must <em>not</em> meet any of the following criteria (criteria 17, 18, 19, and 21 are generic to RAPID):</p>
<ol class="list" style="list-style-type:decimal">
<li><p id="Par111">Known or planned pregnancy; nursing period</p></li>
<li><p id="Par112">Participation in any other interventional clinical trial within the last 30 days before the start of this trial</p></li>
<li><p id="Par113">Simultaneous participation in other interventional trials which could interfere with this trial (simultaneous participation in registry and diagnostic trials is allowed)</p></li>
<li><p id="Par114">Patient without legal capacity who is unable to understand the nature, significance, and consequences of the trial</p></li>
<li><p id="Par115">Previous participation in this trial</p></li>
<li><p id="Par116">Known or persistent abuse of medication, drugs, or alcohol</p></li>
<li><p id="Par117">Person who is in a relationship of dependence/employment with the sponsor or the investigator</p></li>
<li><p id="Par118">Persons deprived of liberty or placed in an institution by judicial or administrative order</p></li>
<li><div class="p" id="Par119">Presence of the following laboratory values at screening<ul class="list" style="list-style-type:square">
<li><div class="p" id="Par120">Platelet count &lt; 100,000/mm<sup>3</sup> (&lt; 100 × 10.<sup>9</sup>/L)</div></li>
<li><div class="p" id="Par121">Neutrophil count &lt; 1500/mm<sup>3</sup> (1.5 × 10.<sup>9</sup>/L)</div></li>
<li><div class="p" id="Par122">Serum creatinine &gt; 1.5 × upper limit of normal (ULN)</div></li>
<li><div class="p" id="Par123">Total bilirubin, GOT, GPT, or gGPT &gt; 1.5 × ULN</div></li>
<li><div class="p" id="Par124">Serum uric acid levels &gt; 1.2 × ULN</div></li>
<li><div class="p" id="Par125">Indirect (unconjugated) bilirubin &gt; 1.2 × ULN</div></li>
</ul>
</div></li>
<li><p id="Par126">Known or suspected Gilbert syndrome (Morbus Meulengracht)</p></li>
<li><p id="Par127">Severe impairment of liver function (Child Pugh class C)</p></li>
<li><p id="Par128">Known history of nephrolithiasis or underlying condition with a strong association of nephrolithiasis, including hereditary hyperoxaluria or hereditary hyperuricemia</p></li>
<li><p id="Par129">History or clinical diagnosis of gout</p></li>
<li><p id="Par130">History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or adequately treated cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.</p></li>
<li><p id="Par131">History of medically significant active, chronic systemic infections (not considering the SARS-CoV-2 infection) within 6 months before day 1, including, but not limited to tuberculosis, hepatitis B, C, or D, and HIV</p></li>
<li><p id="Par132">History or presence of serious or acute heart disease such as uncontrolled cardiac dysrhythmia or arrhythmia, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure (New York Heart Association [NYHA] class 3 or 4)</p></li>
<li><p id="Par133">History or presence of any major medical or psychiatric illness which cannot be controlled by medication (e.g., severe depression, schizophrenia, psychotic disorder), history of suicide attempt, or current suicidal ideation, if any of those conditions in the opinion of the investigator could create undue risk to the patient or could affect adherence with the trial protocol</p></li>
<li><p id="Par134">Ongoing SARS-CoV-2 infection or positive test for SARS-CoV-2 within 14 days prior to enrolment</p></li>
<li><p id="Par135">Pre-COVID history of chronic fatigue syndrome or other fatigue syndromes that are due to associated diseases (e.g., cancer, autoimmune diseases)</p></li>
<li><p id="Par136">Prior use of IMU-838 or a drug prescribed to treat COVID-19 within 30 days</p></li>
<li><p id="Par137">Vaccination for COVID-19 within 28 days prior to enrollment, or other vaccines (influenza, shingles, etc.) within 14 days of enrollment, or planned use of any vaccine until day 84</p></li>
<li><p id="Par138">Any concomitant disease impairing efficacy endpoint analysis, in the opinion of the investigator</p></li>
<li><div class="p" id="Par139">Any use of the following concomitant medications is prohibited during screening:<ul class="list" style="list-style-type:square">
<li><div class="p" id="Par140">Any medication known to significantly increase urinary elimination of uric acid, in particular lesinurad, as well as uricosuric drugs such as probenecid</div></li>
<li><div class="p" id="Par141">Treatments for any malignancy, in particular irinotecan, paclitaxel, tretinoin, bosutinib, sorafinib, enasidenib, erlotinib, regorafenib, pazopanib, and nilotinib</div></li>
<li><div class="p" id="Par142">Any drug significantly restricting water diuresis, in particular vasopressin and vasopressin analogs</div></li>
<li><div class="p" id="Par143">Rosuvastatin at doses of &gt; 10 mg/day</div></li>
<li><div class="p" id="Par144">Methotrexate at doses of &gt; 17.5 mg/week</div></li>
</ul>
</div></li>
<li><p id="Par145">Hypersensitivity to the active substance or to any of the excipients.</p></li>
</ol></section><section id="Sec15"><h3 class="pmc_sec_title">Who will take informed consent? {26a}</h3>
<p id="Par146">If a patient appears to be eligible for the trial, the investigator at the participating sites informs the patient about the trial and ask the patient for their written consent. It is imperative that written consent is obtained prior to any trial-specific procedures. Patients are enrolled in the trial after informed consent has been obtained between day − 7 and day − 14.</p></section><section id="Sec16"><h3 class="pmc_sec_title">Additional consent provisions for collection and use of participant data and biological specimens {26b}</h3>
<p id="Par147">RAPID_REVIVE includes an optional biosample collection as well as a subsequent use of remaining study samples and medical data collected during the study, respectively. These samples and data can be used for further research projects that have been approved in the use and access process of the Netzwerk Universitätsmedizin (NUM). Scientists that requested samples or data for their own research project through this use and access process must obtain a separate ethics vote for their project. This must be applied for at the ethics committee of their location.</p>
<p id="Par148">If a consent for secondary use has been signed by the patient, samples obtained for biomarker assessments but not completely used in the course of the study are stored for the biobank. Additionally, one EDTA blood sample and one saliva sample will be obtained for patients with signed consent for secondary use.</p>
<p id="Par149">The separate ICF for secondary use (Attachment 3) includes in language understandable to laypeople an outline of the important aspects in this regard such as the scientific value of secondary use, responsibilities, the technical infrastructure for data processing, and the regulatory framework including ethical and legal aspects, data protection, and the use and access process. In this context, particular attention is paid to the distinction between study and secondary use. The ICF for secondary use can be employed generically for other arms of the RAPID platform trial, provided that it is funded by the NUM.</p></section></section><section id="Sec17"><h2 class="pmc_sec_title">Interventions</h2>
<section id="Sec18"><h3 class="pmc_sec_title">Explanation for the choice of comparators {6b}</h3>
<p id="Par150">A placebo arm is included due to regulatory recommendations to evaluate benefits and adverse effects in randomized, double-blind, placebo-controlled studies. Because additional treatment is allowed during the entire trial with few exceptions, a placebo arm is justified.</p></section><section id="Sec19"><h3 class="pmc_sec_title">Intervention description {11a}</h3>
<p id="Par151">Overall treatment time is 56 days. Patients in the treatment arm receive IMU-838 22.5 mg/day for a 7-day initiation phase and subsequently IMU-838 45 mg/day for the remaining treatment period. Patients in the control arm receive placebo for 56 days. IMU-838 and placebo (identical to the IMU-838 tablets in appearance, constitution of inactive ingredients, and packaging) are administered once daily as oral tablets. A single tablet is taken once daily in the morning in fasted state (no food after midnight unrestricted intake of water is always allowed) with one glass of water approximately 15 min to 1 h before breakfast.</p></section><section id="Sec20"><h3 class="pmc_sec_title">Criteria for discontinuing or modifying allocated interventions {11b}</h3>
<p id="Par152">Patients receive treatment from day 1 until day 56 or until discontinuation due to intolerable toxicity, withdrawal of consent, loss to follow-up, death, or termination of the trial. They are followed up until day 84 after initiation of treatment. Dose modifications are not permitted during the trial. Any deviation has to be previously discussed with the sponsor unless it concerns patient’s safety. All interruptions must be recorded on the appropriate electronic Case Report Form (eCRF) page.</p></section><section id="Sec21"><h3 class="pmc_sec_title">Strategies to improve adherence to interventions {11c}</h3>
<p id="Par153">Face-to-face adherence reminder sessions (patients and investigator or another appropriate individual who is designated by the investigator) take place at the initial product dispensing and each trial visit thereafter. This session includes:</p>
<ul class="list" style="list-style-type:disc">
<li><p id="Par154">The importance of following trial guidelines for adherence to once daily intake of IMP.</p></li>
<li><p id="Par155">Instructions about taking IMP including timing, storage, and importance of taking IMP, and what to do in the event of a missed dose.</p></li>
<li><p id="Par156">Notification that there will be an IMP count at the day 56 trial visit (used/empty/unsealed/damaged and/or unused packages have to be shown to the investigator).</p></li>
<li><p id="Par157">Importance of calling the clinic if experiencing problems related to IMP such as symptoms or loss or damage of packages.</p></li>
</ul>
<p id="Par158">Subsequent sessions occur at the follow-up visits. Participants are asked about any problems they are having taking their IMP. There are brief discussion of reasons for missed doses and simple strategies for enhancing adherence, e.g., linking IMP taking to meals or other daily activities. Participants will have an opportunity to ask questions and key messages from the initial session will be reviewed as needed.</p></section><section id="Sec22"><h3 class="pmc_sec_title">Relevant concomitant care permitted or prohibited during the trial {11d}</h3>
<section id="Sec23"><h4 class="pmc_sec_title">Permitted concomitant therapy requiring caution and/or action</h4>
<p id="Par159">Restricted concomitant medications are not generally prohibited (Table <a href="#Tab1" class="usa-link">1</a>), but use should be restricted as far as possible in terms of dose and treatment duration. In accordance with the prescribing information, the lowest effective dosage for the shortest duration should be applied based on the individual patient treatment goals whenever possible. Alternatives to these drugs should be considered and patients should be carefully monitored for any indication of overdose and/or toxicity. Care should be exercised when using medications that are substrates of the breast cancer resistance protein (BCRP) transport system, especially where the elimination of the medication depends on the BCRP transport system. Patients should be closely monitored for signs and symptoms of excessive exposure to medicinal products and the dosing of these medicinal products should be carefully considered. This is particularly true for statins, and their dose should be lowered to the lowest possible dose. Specifically, doses of rosuvastatin are not to exceed 10 mg daily.</p></section></section><section id="Sec24"><h3 class="pmc_sec_title">Prohibited concomitant therapy</h3>
<p id="Par160">Any use of the following concomitant medications is prohibited during screening and throughout the duration of the trial (exclusion criteria 23):</p>
<ul class="list" style="list-style-type:disc">
<li><p id="Par161">Any medication known to significantly increase urinary elimination of uric acid, in particular lesinurad, as well as uricosuric drugs such as probenecid.</p></li>
<li><p id="Par162">Treatments for any malignancy, in particular irinotecan, paclitaxel, tretinoin, bosutinib, sorafinib, enasidenib, erlotinib, regorafenib, pazopanib, and nilotinib.</p></li>
<li><p id="Par163">Any drug significantly restricting water diuresis, in particular vasopressin and vasopressin analogs.</p></li>
<li><p id="Par164">Rosuvastatin at doses of &gt; 10 mg/day.</p></li>
<li><p id="Par165">Methotrexate at doses of &gt; 17.5 mg/week.</p></li>
</ul>
<p id="Par166">If such agents are required for a patient, the patient has to discontinue the trial treatment and the given prohibited therapy has to be recorded in the eCRF.</p></section><section id="Sec25"><h3 class="pmc_sec_title">Provisions for post-trial care {30}</h3>
<p id="Par167">After end of the trial, the therapy of PCS will be performed according to the trial site’s routine. A subject insurance according to applicable law has been taken out with for all subjects participating in the clinical trial. The insurance covers all harms that resulted from trial participation.</p></section><section id="Sec26"><h3 class="pmc_sec_title">Outcomes {12}</h3>
<p id="Par168">Table <a href="#Tab2" class="usa-link">2</a> shows the objectives and related endpoints.
</p></section><section id="Sec27"><h3 class="pmc_sec_title">Participant timeline {13}</h3>
<p id="Par169">A detailed flowchart for RAPID_REVIVE is provided in Table <a href="#Tab3" class="usa-link">3</a>. The schedule of assessment lists all of the assessments and indicates with an “X” when they have to be performed. Screening evaluations have to be performed within 7 days prior to randomization. During the course of the trial, visits and test procedures should occur on schedule whenever possible; after day 1, visits that occur ± 3 days from the scheduled date will not constitute any protocol deviation. Two visits, days 14 and 84, are held as Videoconference visits using a digital health application (SaniQ) or phone, alternatively. After being informed about the trial and after giving their written informed consent, patients have to undergo the examinations listed in Table <a href="#Tab3" class="usa-link">3</a> prior to randomization. All women of childbearing potential must undergo a pregnancy test. In addition, the following parameters are assessed at screening: differential blood count, serum creatinine, blood urea nitrogen, blood uric acid, GOT, GPT, AP, gGT, total bilirubin, indirect bilirubin, amylase, lipase, glucose, triglycerides, tuberculosis interferon gamma release assay (TBC IGRA). Results of examinations routinely performed due to PCS are accepted, if they were done within 2 weeks prior to randomization. Patients must meet all inclusion criteria and none of the exclusion criteria to be considered eligible. The randomization and subsequent allocation of participants to treatments will take place directly after eligibility screening. Randomization is performed in the secuTrial® database in a 1:1 randomization ratio during an initialization phase thereafter using a response-adaptive randomization procedure. Following inclusion in the trial (day − 7), the patients should visit the trial site on days 1, 28, and 56. On days 14 and 84, the patients will be contacted via a video-conference or phone call. On day 1, patients come to the trial site, in order to receive and initiate the IMP. Patients are treated for 56 days. A cerebral magnetic resonance imaging (cMRI) is performed in a subset of patients at baseline.
</p>
<section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>Visit schedule and assessments RAPID_REVIVE</p></div>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12366011_13063_2025_9008_Tab3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5c1f/12366011/d64f7f887bc9/13063_2025_9008_Tab3_HTML.jpg" loading="lazy" id="MO2" height="708" width="778" alt="graphic file with name 13063_2025_9008_Tab3_HTML.jpg"></a></p>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p153"><p>
<sup>i</sup>Initiation of treatment with the IMP is defined as day 1 (V3-SOT) after completion of sensory device measurements. V3-SOT may be delayed for max. 7 days after completion of sensory device measurements
<sup>ii</sup>The following parameters will be assessed at screening: differential blood count, serum creatinine, blood urea nitrogen, blood uric acid, GOT, GPT, AP, gGT, total bilirubin, indirect bilirubin, amylase, lipase, glucose, triglycerides, tuberculosis interferon gamma release assay (TBC IGRA). In addition, the following assessments will be performed to assess inclusion criteria: FSS, mMRC, PST, and MoCa
<sup>iii</sup> Includes SF-36, FSS, GAD-7, mMRC, PEM Score, PHQ-9, PHQ-15, PHQ-stress (FSS and mMRC are not required at V2-Enrollment and Baseline)
<sup>iv</sup> Includes 1MSTS, PST, MoCA (MoCA and PST are not required at V2-Enrollment and Baseline)
<sup>v</sup> Measurement using the Garmin Vivosmart 5HEALTH (Qurasoft GmbH) with the SaniQ Integration software and the c-med alpha (ear sensor) and the cosinuss Health Platform (Cosinuss GmbH) over a duration of 7 days each. After enrollment at the study site, patients will be instructed on how to use the sensory devices and the first 7 days of measurement will be initiated. Measurements need to be completed before SOT Visit C2 on day 1. The second and third period of sensory device measurements will start between day 19 and day 21 to be completed before Visit C3 at day 28 assessment and between day 47 and day 49 to be completed before Visit C4 at day 56 EOT assessment
<sup>f</sup> Only necessary if Screening and Enrollment/Baseline visit are more than 48 h apart. Differential blood count only
<sup>g</sup> Differential blood count, serum creatinine, blood urea nitrogen, blood uric acid, GOT, GPT, AP, gGT, total bilirubin, indirect bilirubin, amylase, lipase, glucose, triglycerides
<sup>h</sup> cMRI will be performed at the Enrollment Visit for a subgroup of 100 patients. For organizational reasons, regular Enrollment Visit assessments and the cMRI appointment may not always be feasible to arrange on the same date. Therefore, the cMRI may be performed until day 7. If the sensory devices have already been placed on the patient, they may have to be removed for the duration of the cMRI, but should be placed back on afterward
</p></div></div></section></section><section id="Sec28"><h3 class="pmc_sec_title">Sample size {14}</h3>
<p id="Par170">In the setting of adaptive platform trials, sample size planning is done by extensive simulations to ensure the robustness of the trials under various deviations from analysis assumptions.</p>
<p id="Par171">At this preliminary stage and given the novelty of PCS as a disease entity, only core characteristics of a generic sample size plan are given. As the precise effect size of IMU-838 in patients with PCS is unknown, the calculation for the starting sample size of this APT is based on the assumption that an improvement in terms of a standardized mean difference (Cohen’s <em>d</em>) of about 0.4 in the primary endpoint would be considered clinically meaningful. The sample size calculation is thus based on the comparison of 2 means of score outcomes of the SF-36-PF (primary endpoint), using a <em>t</em>-test (although a more complex and more powerful analysis model will be used as primary analysis). With 1:1 allocation, a sample size of <em>n</em> = 150 patients per group yields a power of 1 − <em>β</em> = 0.90 given a standardized mean difference (Cohen’s <em>d</em>) of 0.376. To adjust for a potential drop-out rate of 20% overall, another 38 patients need to be randomized per group. Thus, the total sample size across the two groups is 376 patients. If feasible, given funding period and resources, larger sample sizes are aimed for.</p>
<p id="Par172">Calculations were performed using nQuery 9—Power and Sample Size for Group Sequential Trails (version 9.2.1.0).</p></section><section id="Sec29"><h3 class="pmc_sec_title">Recruitment {15}</h3>
<p id="Par173">Patient recruitment is supported by the already established, central trial infrastructures of the 3 NAPKON platforms. A recent feasibility inquiry identified more than 1000 patients with shortness of breath, more than 2000 patients with acute or persistent neurological impairment like fatigue or brain fog, and more than 2000 patients with gastrointestinal or cardiovascular symptoms or body aches in the NAPKON-SUEP and NAPKON-POP cohorts by March 2023. A minimum of 1500 patients suffered from at least 2 PCS symptoms of moderate or severe intensity. These patients had already given their consent to be re-contacted as part of the initial NAPKON informed consent. Apart from these patients, further potential trial participants may be identified through the PCS ambulatory care structures established at the different trial sites. Each site alone has seen at least 500 patients with PCS over the last 2 years. These patients may be contacted and screened through these established structures. Finally, the project partners representing patient-related concerns also intend to use their extensive networks, including access to a large community organized in social media platforms and a primary care physician network in order to identify further patients that may be suitable for participation in the trial.</p></section></section><section id="Sec30"><h2 class="pmc_sec_title">Assignment of interventions: allocation</h2>
<section id="Sec31"><h3 class="pmc_sec_title">Sequence generation {16a}, concealment mechanism {16b}, implementation {16c}</h3>
<p id="Par174">The randomization code was generated by a statistician and provided to data management for implementation in secuTrial®. Patients are randomized using block randomization stratified by center in a 1:1 randomization ratio during an initialization phase to minimize the risk of extreme imbalance resulting in some high variable treatment effect estimates early in the trial. The initiation phase will be completed once the first 150 patients reach day 56. Following the initiation phase, patients will be allocated to the treatment arms using a response-adaptive randomization procedure to favor the more effective treatment arm, while maintaining a minimum power. The randomization ratio will be adapted at regular intervals based on the outcomes observed up to that point.</p>
<p id="Par175">The randomization and subsequent allocation of participants to treatments takes place directly after eligibility screening. Randomization is performed in the secuTrial® database by on-site study personnel.</p></section></section><section id="Sec32"><h2 class="pmc_sec_title">Assignment of interventions: blinding</h2>
<section id="Sec33"><h3 class="pmc_sec_title">Who will be blinded {17a}</h3>
<p id="Par176">RAPID_REVIVE is a double-blind trial, neither the patients nor the investigator knows which treatment participants are receiving. The trial statistician is blinded until the end of the recruitment. After the end of the recruitment period, he will perform a blind review of data, i.e., assessment and checking for consistency and plausibility without information on the randomized treatment for each patient. Then he will be unblinded for the final analysis.</p></section><section id="Sec34"><h3 class="pmc_sec_title">Procedure for unblinding if needed {17b}</h3>
<p id="Par177">As a matter of principle, unblinding in clinical trials is only performed after closure of the database for the final analysis. However, the coding system for the IMPs includes a mechanism that permits rapid identification of the product(s) in case of a medical emergency, but does not permit undetectable breaks of the blinding (ICH-GCP 5.13.4).</p>
<p id="Par178">Any of the following can be reasons for premature unblinding:</p>
<ul class="list" style="list-style-type:disc"><li><p id="Par179">In emergency situations, if it is necessary for the trial patient’s safety, i.e., if the further treatment depends on the knowledge of the IMP.</p></li></ul>
<p id="Par180">To allow emergency unblinding, the investigator is supplied with a set of emergency envelopes, i.e., a sealed envelope for each treated trial patient that, if opened, reveals the treatment assigned to that patient. If emergency unblinding of a patient is necessary, the investigator will open the emergency envelope (based on the treatment/randomization/medication number) and has to enter date and time as well as their name and signature on the unblinding form contained in the envelope. The investigator also has to fax the form to the representative of the sponsor immediately.</p>
<ul class="list" style="list-style-type:disc">
<li><p id="Par181">In the event of accidental administration of the IMP to a person who is not a trial patient.</p></li>
<li><p id="Par182">In the event of administration of an incorrect dose, in particular overdose of IMP which might put the patient at risk.</p></li>
</ul>
<p id="Par183">The decision of whether unblinding is necessary lies with the investigator. If possible, the sponsor/coordinating investigator should be consulted first.</p>
<ul class="list" style="list-style-type:disc"><li><p id="Par184">In the event of a SUSAR.</p></li></ul>
<p id="Par185">In case of a SUSAR, unblinding is performed by the person responsible for the pharmacovigilance/safety management in the trial. The blinding should be maintained for persons responsible for the ongoing conduct of the trial.</p></section></section><section id="Sec35"><h2 class="pmc_sec_title">Data collection and management</h2>
<section id="Sec36"><h3 class="pmc_sec_title">Plans for assessment and collection of outcomes {18a}</h3>
<p id="Par186">RAPID_REVIVE includes a screening period of 7 days, a double-blind treatment period of 56 days and a follow-up period of 28 days. Participants are followed up for 84 days from the day of randomization. Clinic visits are scheduled at screening, day 1 (enrollment and baseline), day 28, and day 56 to assess efficacy and safety. Videoconference visits are scheduled at days 14 and 84. Once consented, the baseline data collection of the participant takes place on the trial site. The baseline visit includes the measurement of vital signs (heart rate and blood pressure), a physical examination, a safety laboratory, and the documentation of concomitant medication. In addition, all women of childbearing potential must undergo a pregnancy test. In a subset of 100 patients, cMRI is performed. Safety laboratory and the pregnancy test are also analyzed on days 28 and 56 as designated in Table <a href="#Tab3" class="usa-link">3</a> visit schedule and assessment. Safety laboratory includes the following parameters: blood count, serum creatinine, blood urea nitrogen, blood uric acid, GOT, GPT, AP, gGT, total bilirubin, indirect bilirubin, amylase, lipase, glucose, triglycerides, tuberculosis interferon gamma release assay (TBC IGRA).</p>
<p id="Par187">Furthermore, the baseline patient-reported outcome measures (PROMs) are performed. Telemedical software (SaniQ Praxis; CE medical device, Qurasoft GmbH, Koblenz) is used to support acquisition of the PROMs as indicated below.</p>
<section id="Sec37"><h4 class="pmc_sec_title">PROMs</h4>
<section id="FPar1"><h5 class="pmc_sec_title">Short Form-36 (SF-36 (RAND 1992))</h5>
<p id="Par188">The Short Form-36 (SF-36) questionnaire is an established and widely used health-related quality of life measure. The SF-36 comprises 8 domain scores including “physical functioning” (SF-36 PF). While SF-36 PF is used to assess the primary endpoint of this protocol, the complete SF-36 is needed for secondary endpoint assessment. The SF-36 PF asks respondents to report limitations on 10 mobility activities, such as walking specified distances, carrying groceries, and bathing or dressing and has been shown to be a useful tool to measure mobility disability. The possible scores range from 0 (worst, greatest limitation) to 100 (best). The SF-36 is reported via SaniQ.</p></section><section id="FPar2"><h5 class="pmc_sec_title">Fatigue SeverityScale (FSS [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>])</h5>
<p id="Par189">The FSS questionnaire contains nine statements that rate the severity of fatigue symptoms from 1 to 7 for each question. A low value (e.g., 1) indicates strong disagreement with the statement, whereas a high value (e.g., 7) indicates strong agreement. A higher score (36 or above) may indicate the patient is suffering from fatigue. </p></section><section id="FPar3"><h5 class="pmc_sec_title">GeneralizedAnxiety Disorder Scale-7 (GAD-7 [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>])</h5>
<p id="Par190">The GAD-7 is a brief instrument designed to assess generalized anxiety disorder. The 7 items of the GAD-7 test the most important diagnostic criteria of Generalized Anxiety Disorder according to the DSM-IV and ICD-10 criteria. All items are answered for the period of the last 2 weeks and rated on a 4-point response scale with scores running from 0 (not at all) to 3 (nearly every day) for each question and the total score ranges from 0 to 21. A total score of 0 to 4 represents minimal anxiety; 5 to 9, mild anxiety, 10 to 14, moderate anxiety; and 15 to 21, severe anxiety.</p></section><section id="FPar4"><h5 class="pmc_sec_title">Patient HealthQuestionnaire (PHQ)—modules</h5>
<p id="Par191">The PHQ is an internationally available, valid, and easy to use self-report instrument for assessing common psychiatric disorders. Severity of mental disorder symptoms such as depression, anxiety, somatization, and distress are measured with the following PHQ-modules (all are reported via SaniQ).</p></section><section id="FPar5"><h5 class="pmc_sec_title">-Patient Health Questionnaire-9 [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]</h5>
<p id="Par192">The PHQ-9 is a 9-question instrument given to patients to screen for the presence and severity of depression. Patients are asked the number of days in the past 2 weeks they had experienced depressive symptoms with scores running from 0 (not at all) to 3 (nearly every day) for each question and a total score from 0 to 27.</p></section><section id="FPar6"><h5 class="pmc_sec_title">- PHQ-15 [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>]</h5>
<p id="Par193">The PHQ-15 covers 15 of the most prevalent DSM-IV symptoms of somatization disorder for a period of 4 weeks, each symptom score ranging from 0 (best option) to 2 (worst option). The total PHQ 15 score ranges from 0 to 30 and scores of 5, 10, and 15, represent cutoff points for low, medium, and high somatic symptom severity, respectively.</p></section><section id="FPar7"><h5 class="pmc_sec_title">-PHQ-stress [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>]</h5>
<p id="Par194">The PHQ-stress measures psychosocial strain during the last month by 10 items including health, work/financial, social, and traumatic stress. Ratings comprise “not at all bothered” (0), “bothered a little” (1), and “bothered a lot” (2). The total PHQ stress score ranges from 0 to 20. A total score of 0 to 4 represents minimal psychosocial strain; 5 to 9, mild psychosocial strain, 10 to 14, moderate psychosocial strain; and 15 to 21, severe psychosocial strain.</p></section><section id="FPar8"><h5 class="pmc_sec_title">mMRC (Modified Medical Research Council Dyspnea Scale [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>])</h5>
<p id="Par195">The mMRC is used to assess the degree of baseline functional disability due to dyspnea. Symptoms of dyspnea are rated by the patient from 0 to 4, with a higher score indicating worse breathlessness. The mMRC will be reported via SaniQ, Sect. 7.5.9.</p></section><section id="FPar9"><h5 class="pmc_sec_title">Post-ExertionalMalaise (PEM) questionnaire [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>]</h5>
<p id="Par196">The patient indicates the severity and frequency of 5 statements (from the DePaul Symptom Questionnaire) about post-exertional malaise over the last 6 months on a scale from 0 to 4 (a higher score indicating worse symptoms). At all visits following day 1, the period covered should not be 6 months, but the time since the last visit at which the PEM questionnaire was completed. The PEM is reported via SaniQ.</p>
<p id="Par197">PROMs are performed furthermore at days 28, 56, and 84 (Table <a href="#Tab3" class="usa-link">3</a>).</p></section></section><section id="Sec38"><h4 class="pmc_sec_title">Physician-reported outcome measures</h4>
<p id="Par198">Physician-reported outcome measures are performed at baseline, day 28, and day 56, and include:</p>
<section id="FPar10"><h5 class="pmc_sec_title">Montreal-CognitiveAssessment (MoCA [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>])</h5>
<p id="Par199">The MoCA is a validated, internationally used rapid assessment for cognitive impairment. It is currently the best alternative to computerized tests. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. For the test, patients are instructed by a health professional to perform 11 different short tasks. A standardized form is used to support the assessments and document the results. The test results range between 0 and 30 points, where results of 26 and higher are considered normal. The assessment requires approximately 10 min.</p></section><section id="FPar11"><h5 class="pmc_sec_title">1-min sit-to-stand test (1MSTST)</h5>
<p id="Par200">The 1MSTST quantifies exercise capacity. It typically involves an armless chair and the performance of as many sit-to-stand actions as possible in 1 min without using the upper limbs. The number of repetitions is measured.</p></section><section id="FPar12"><h5 class="pmc_sec_title">Passive standingtest (PST [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>])</h5>
<p id="Par201">An automated blood pressure cuff is placed on the right upper limb, recording blood pressure and HR at 1-min intervals throughout the test. After 5 min of supine posture, the patient stands with their heels 2–6 in. away from the wall and with the upper back leaning comfortably against the wall. The patient remains in this position for a maximum of 10 min and is asked to minimize movement. At the end of the 5-min supine and each minute during the PST, the blood pressure and HR are recorded; thereafter, the patient is asked about the severity of orthostatic symptoms on a 0 to 10 scale.</p></section></section><section id="Sec39"><h4 class="pmc_sec_title">Sensory device measurement</h4>
<p id="Par202">Intra-patient change in autonomic function and physical activity parameters are measured by the use of mhealth sensory devices (c-med alpha, CE medical device, Cosinuss GmbH, Munich, Germany, and SaniQ, CE medical device, Qurasoft GmbH, Koblenz, Germany). The following measurements are recorded by the respective devices:</p>
<ul class="list" style="list-style-type:disc">
<li><p id="Par203">SaniQ + smartwatch vivosmart 5: global activity (steps/24 h), wear time (min), time spent in physical activity (min), resting (bpm), and activity heart rate (bpm),</p></li>
<li><p id="Par204">Cosinuss: heart rate deceleration, heart rate turbulence, nocturnal heart rate, nocturnal respiratory rate, expiration-triggered sinus arrhythmia, baroreflex sensitivity, frequency of spontaneous ectopic beats.</p></li>
</ul>
<p id="Par205">Measurements take place at three different times during the study, with each measurement period lasting 7 consecutive days (see Table <a href="#Tab3" class="usa-link">3</a>):
</p>
<ul class="list" style="list-style-type:disc">
<li><p id="Par206">Measurement Period 1 at baseline: After consent, measurement needs to be initiated between day − 10 and − 7 and completed until day 1.</p></li>
<li><p id="Par207">Measurement Period 2 at MOT: Measurement starts between day 19 and 21 and lasts for 7 days.</p></li>
<li><p id="Par208">Measurement Period 3 at EOT: Measurement starts between day 47 and 49 and lasts for 7 days.</p></li>
</ul>
<p id="Par209">Primary analysis of the data acquired by the two digital sensors and their connected software is performed by the MRI (Cosinuss ear sensor data) and UKGM team (smartwatch data), respectively. This includes the transformation of timeline-data to numerical data of the autonomic function and physical activity parameters (parameters described in Outcomes, Key secondary endpoint 4.) The processed data are then exported into the central trial statistics (secuTrial®) from the UKGM team and the MRI team respectively.</p></section><section id="Sec40"><h4 class="pmc_sec_title">Biomarker assessments</h4>
<p id="Par210">The NUM Biosample Core Unit (NUM-BCU) stores the samples for biomarker analyses, which are collected at certain intervals from the respective trial sites, centrally in Hanover or Bielefeld. Initially, samples are collected, processed, and stored locally at the trial site following the (Standard Operating Procedures) SOPs of the NUM-BCU. These processes are documented in the central biosample system (NUM-LIMS).</p>
<p id="Par211">NUM-BCU will ship probes to the central analysis laboratories.</p>
<p id="Par212">An in-depth biomarker assessment will be performed for all baseline samples. Samples from further visits (day 28 and day 56, see Table 3) will be stored for potential future analysis.</p>
<p id="Par213">Two central laboratories (Goethe University Frankfurt, Charité – Universitätsmedizin Berlin) will perform biomarker assessments. Analysis results will be documented in the central biosample system (NUM-LIMS).</p>
<p id="Par214">At the laboratory in Frankfurt, the following parameters will be assessed:</p>
<ul class="list" style="list-style-type:disc">
<li><p id="Par215">SARS-CoV-2 neutralizing antibodies (serum)</p></li>
<li><p id="Par216">EBV and CMV serology (serum)</p></li>
<li><p id="Par217">Detection of EBV by PCR (DNA from blood)</p></li>
<li><p id="Par218">Detection of SARS-CoV-2 by RT-PCR (DNA from feces)</p></li>
</ul>
<p id="Par219">At the laboratory in Berlin, the following parameters will be assessed:</p>
<ul class="list" style="list-style-type:disc">
<li><p id="Par220">Cytokines and chemokines (e.g., CRP, type I IFN, IL-4, IL-6, IL-1b, IL-8, IL-10, TNF, IP-10, MCP-1, MIP-3b; serum, heparin plasma, EDTA blood)</p></li>
<li><p id="Par221">Antibodies and autoantibodies (e.g., anti-type I IFN, anti-GPCRs G-protein-coupled receptors; serum and heparin plasma)</p></li>
<li><p id="Par222">Storage for later analysis: serum for proteomics</p></li>
<li><p id="Par223">Cytometry (CyTOF; heparin blood)</p></li>
<li><p id="Par224">Functional analyses of immune cell subsets (PBMCs from heparin plasma)</p></li>
<li><p id="Par225">Storage for later analysis: scRNAseq (PBMCs from heparin plasma)</p></li>
<li><p id="Par226">Complement cleavage products (EDTA plasma)</p></li>
<li><p id="Par227">Storage for later analysis: plasma for proteomics (EDTA plasma)</p></li>
</ul></section></section><section id="Sec41"><h3 class="pmc_sec_title">Plans to promote participant retention and complete follow-up {18b}</h3>
<p id="Par228">Measures to increase any patient’s inclination to complete the study always address the patient directly. Patients suffering from PCS frequently report a perceived lack of recognition by the public and health care and scarce acknowledgement of the setback they experience from their health condition. Therefore, it is necessary to take the patients’ concerns seriously and particularly important to guide and give participation by the trial staff. In case of no perceived amelioration, the patient needs to be encouraged to complete the trial anyhow. Also, the telemetric and biometric devices should function smoothly and pose no annoyance for the user, and if, help should be offered from the trial site. The recruitment will take into consideration that during the roughly 3 months on the trial, visits might interfere with holidays during the festive season.</p>
<p id="Par229">In the case trial treatment of a patient has been stopped prematurely, further follow-up visits (EOS) and the assessment of the trial endpoints are essential to enable an analysis of the full analysis set according to the intention-to-treat principle. Further visits, follow-up, and documentation should always be striven for/ensured in this case. This includes the follow-up of AEs, the time of termination, the results available at that time and, if known, the documentation of the termination of treatment in the eCRF and in the medical record, giving reasons, a final examination, and documentation according to the protocol (if possible).</p></section><section id="Sec42"><h3 class="pmc_sec_title">Data management {19}</h3>
<p id="Par230">The investigator records the participation in the trial, the frequency of the trial visits, the relevant medical data, the concomitant treatment, and the occurrence of adverse events in the medical record of each trial patient. An electronic data capture (EDC, secuTrial®) system is used in this trial (called eCRF). All data collected during the trial are entered in the trial-specific e-forms by the responsible investigator, or designated person, as timely as possible. Data entry and data corrections on e-forms are automatically tracked in the audit trail created by the EDC system. Data corrections in the eCRF due to queries are performed by the responsible investigator, or designated person, as timely as possible.</p>
<p id="Par231">Data management is performed with secuTrial® which is developed, validated, and maintained by interactive Systems GmbH. The database is installed on servers of the University Medical Center Göttingen (UMG) and backed up daily. Daily backups are saved for 14 days. Details on data management (procedures, responsibilities, data corrections, if any, which may be made by data management staff themselves, etc.) are described in a data management plan prior to the trial. Before any data entry is performed, the trial database will be validated and undergo a user-test. An audit trail is created to provide an electronic record of which data were entered or subsequently changed, by whom and when. R- or SAS software is used to review the data for completeness, consistency, and plausibility in cases a direct implementation is not possible. Upon discovering inconsistencies or implausible data, queries are sent to the investigator for review. After database deactivation a copy of the database will be password encrypted and archived for 25 years within the UMG. If consent is given, long-term storage of data for secondary use is provided in a separate research database.</p></section><section id="Sec43"><h3 class="pmc_sec_title">Confidentiality {27}</h3>
<p id="Par232">The investigator must ensure anonymity of the patients; patients must not be identified by names in any documents submitted to sponsor. Signed informed consent forms (ICF) and patient enrollment log must be kept strictly confidential to enable patient identification at the site.</p>
<p id="Par233">All trial-related information is stored securely at the trial site. All participant information are stored in locked file cabinets in areas with limited access. All laboratory specimens, reports, data collection, process, and administrative forms are identified by a coded identification number only, to maintain participant confidentiality.</p>
<p id="Par234">Identity management, pseudonymization of data, and informed consent management are handled by the independent Trusted Third Party (TTP). Imaging data are handled through a centralized Digital Imaging and Communications in Medicine (DICOM) administrative system (DIMA). The collection of bio samples are performed in accordance with SOPs generated by the NUKLEUS Biobanking Core Unit (BCU).</p></section><section id="Sec44"><h3 class="pmc_sec_title">Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use {33}</h3>
<p id="Par235">Samples obtained for biomarker assessments that are initially stored at the trial site are shipped to central laboratories in the course of the study. Remaining material will be stored for the biobank for secondary use. Secondary use refers to medical research aimed at improving the prevention, detection, and treatment of diseases. As part of secondary use, further molecular and genetic analysis can be carried out on the samples. Patients are informed about this in the consent for secondary use. See also section “<a href="#Sec16" class="usa-link">Additional consent provisions for collection and use of participant data and biological specimens {26b}</a>”.</p></section></section><section id="Sec45"><h2 class="pmc_sec_title">Statistical methods</h2>
<section id="Sec46"><h3 class="pmc_sec_title">Statistical methods for primary and secondary outcomes {20a}</h3>
<p id="Par236">Before the start of the final analysis of the first intervention (RAPID_REVIVE) included in the platform trial, a statistical analysis plan (SAP) that encompasses the entire platform study will be prepared for the master protocol. The SAP will be completed during the “blind review” of the data, at the latest. This blind review, i.e., assessment and checking for consistency and plausibility of data, will be performed after the end of the recruitment period without information on the randomized treatment for each patient. The analysis of the primary endpoint is generic to all interventions of the platform trial including RAPID_REVIVE and is also described in the master protocol. The analysis of secondary endpoints is specific for the ISAs and clarified here for RAPID_REVIVE.</p></section><section id="Sec47"><h3 class="pmc_sec_title">Statistical methods for primary outcome</h3>
<p id="Par237">The primary endpoint of the RAPID platform trial is physical function measured by SF-36-PF at day 56, a continuous variable ranging from 0 to 100 with smaller values indicating greater limitations. The primary outcomes in the strata will be analyzed using mixed models for repeated measures (MMRM) approaches, i.e., Gaussian linear models for repeated measures with treatment, center, time, center, and treatment-by-time interactions as factors, and baseline measurements as covariate. The error terms are assumed to follow a multivariate normal distribution with unstructured covariance. Least squares mean changes from baseline to day 56 will be reported for both groups with 95% confidence interval (CI) as well as the difference between the least squares treatment group means with 95% CI and <em>p</em>-value testing the null hypothesis of no treatment effect. Although the models described are robust to a certain extent to missing data, sensitivity analyses will be performed as supporting analyses including reference-based multiple imputation and shared random effects models. Although the response adaptive randomization procedure maintains consistency and asymptotic normality of estimators under simple conditions [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>], we will perform a re-randomization test as sensitivity analysis.</p></section><section id="Sec48"><h3 class="pmc_sec_title">Statistical methods for secondary outcomes</h3>
<p id="Par238">Secondary endpoints SF-36, FSS, PHQ-9, GAD-7, PHQ-15, PHQ-stress, MoCA, mMRC, PEM, PST, 1MSTST, and continuous health activity parameters of RAPID_REVIVE are analyzed analogously to the primary endpoint described above with additional least square mean comparisons between at days 28 and 84. Likewise, changes in biomarkers from baseline to day 56, such as cytokines and chemokines will also be evaluated analogously to the primary endpoint.</p>
<p id="Par239">For secondary endpoints only involving changes from baseline to day 28, a linear regression model, with treatment and center as factors, and the baseline measurement as covariates will be employed. Treatment effects will be reported as the difference between least squares means for treatment groups, accompanied by a 95% CI and a <em>p</em>-value for testing the null hypothesis of no treatment effect. All hypothesis tests are performed two-sided at 5% significance level, unless stated otherwise.</p></section><section id="Sec49"><h3 class="pmc_sec_title">Interim analyses {21b}</h3>
<p id="Par240">Multiple interim analyses are planned be conducted by the Data Safety Monitoring Board (DSMB) to monitor efficacy and safety of the study interventions in the master protocol RAPID. The adaptive platform trial infrastructure facilitates the ongoing evaluation of emerging therapies in terms of efficacy and safety in stratified populations. Over time the therapies included in the platform as well as the strata can change as new evidence regarding the efficacy and safety of treatments as well as the population stratification emerges from within the platform trial or outside the trial (e.g., as part of systematic reviews [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>]). These adaptations of the platform will be facilitated through the regular interim analyses by the DSMB and the trial statistician [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>]. The function of the DSMB is to monitor the course of the trial and if necessary to give a recommendation to the sponsor/coordinating investigator/SC for discontinuation, modification, or continuation of the trial.</p>
<p id="Par241">Interim analysis for, e.g., futility or efficacy stopping, adaptive enrichment, or re-stratification are intervention specific and not described in the master protocol.</p>
<p id="Par242">For RAPID_REVIVE no interim analyses for futility or efficacy stopping are planned. At regular intervals, interim data will be provided to a statistician to generate the randomization code using a response adaptive randomization procedure. The first interim look for the response-adaptive randomization procedure in RAPID_REVIVE is planned after 150 patients reach day 56.</p></section><section id="Sec50"><h3 class="pmc_sec_title">Methods for additional analyses (e.g., subgroup analyses) {20b}</h3>
<p id="Par243">An exploratory objective of the RAPID_REVIVE ISA is to identify blood and imaging biomarkers, as well as clinical characteristics that allow the pre-selection of patients with a high response to the interventional treatment.</p>
<p id="Par244">A subgroup of 100 patients receive a cMRI to allow for adaptation of inclusion criteria over the course of the trial.</p>
<p id="Par245">The cMRI parameters are</p>
<ul class="list" style="list-style-type:disc">
<li><p id="Par247">Limbic system microstructural integrity measured as fractional anisotropy and mean diffusivity in deep gray matter structures</p></li>
<li><p id="Par248">Gray matter thickness in the orbitofrontal cortex, parahippocampal gyrus, insula, and anterior cingulate</p></li>
<li><p id="Par249">Hippocampal volume, thalamic volume, and whole brain volume assessed in a subgroup of 100 patients</p></li>
</ul>
<p id="Par250">For all 376 patients, a biomarker analysis is performed at baseline.</p>
<p id="Par251">Biomarkers measured at baseline, i.e.:</p>
<ul class="list" style="list-style-type:disc">
<li><p id="Par253">Cytokines and chemokines (Type I IFN, IL-4, IL-6, IL-1b, IL-8, IL-10, TNF, IP-10, MCP-1, MIP-3b)</p></li>
<li><p id="Par254">Markers of inflammation and neuronal damage (e.g., C3a, C5a, CRP, GFAP, BDNF, NF L, S100A8/A9)</p></li>
<li><p id="Par255">Viral proteins and serology (SARS-CoV-2: neutralizing antibodies and DNA from feces; EBV DNA from blood)</p></li>
<li><p id="Par256">Autoantibodies (e.g., anti-type I IFN, anti-G-protein-coupled receptors)</p></li>
<li><p id="Par257">Immune cell composition and activation</p></li>
</ul>
<p id="Par258">For this purpose, the baseline cMRI parameters and their interaction with treatment will be included in the regression models described above for the primary and key secondary endpoints. An analogous analysis is performed for biomarkers measured at baseline.</p></section><section id="Sec51"><h3 class="pmc_sec_title">Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c}</h3>
<p id="Par259">Efficacy analyses will be performed primarily in the full analysis set (FAS) according to the intention-to-treat (ITT) principle. This means that the patients will be analyzed in the treatment arms to which they were randomized, irrespective of whether they refused or discontinued the treatment or whether other protocol violations are revealed.</p>
<p id="Par260">The per-protocol (PP) population is a subset of the FAS and is defined as the group of patients who had no major protocol violations, received a predefined minimum dose of the treatment and underwent the examinations required for the assessment of the endpoints at relevant, predefined times. The analysis of the PP population will be performed for the purpose of a sensitivity analysis.</p>
<p id="Par261">Safety analyses will be performed in the safety analysis set. Patients in the safety population are analyzed as belonging to the treatment arm defined by treatment received.</p></section><section id="Sec52"><h3 class="pmc_sec_title">Plans to give access to the full protocol, participant-leveldata, and statistical code {31c}</h3>
<p id="Par262">This protocol is posted in the EU Clinical Trial Register (CTIS). In addition, upon trial completion, the results of this trial will be submitted for publication and/or posted in a publicly accessible database of clinical trial results irrespective of the results of the trial.</p>
<p id="Par263">The key aspects and underlying rules and measures regarding the transfer of data and biospecimen for secondary use projects through the University Medicine Network (NUM) Use and Access Process are described in the separate ICF for secondary use (Attachment 3).</p></section></section><section id="Sec53"><h2 class="pmc_sec_title">Oversight and monitoring</h2>
<section id="Sec54"><h3 class="pmc_sec_title">Composition of the coordinating center and trial steering committee {5d}</h3>
<p id="Par264">The sponsor of RAPID is the Goethe University Frankfurt represented by the principal investigator (PI). The coordinating study center of RAPID_REVIVE is the Infectiology focus at the University Hospital Frankfurt. The clinical trial coordination is supported by the Clinical Trials Unit (CTU), University Medical Center, Göttingen (UMG). The UMG is also responsible for Monitoring, Pharmacovigilance, Data management, Randomization, and Biostatistics of RAPID.</p>
<p id="Par265">The governance of RAPID will be key to ensuring its smooth set-up and conduct. The governance consists of.</p>
<ul class="list" style="list-style-type:disc">
<li><p id="Par266"> The scientific steering committee (SC),</p></li>
<li><p id="Par267">The data safety monitoring board (DSMB), and.</p></li>
<li><p id="Par268">The statistical analysis center (SAC).</p></li>
</ul>
<section id="Sec55"><h4 class="pmc_sec_title">Steering commitee</h4>
<p id="Par269">A trial related steering committee (SC) has appointed by the sponsor prior to the start of the trial. The SC is responsible for the management and conduct of RAPID and is composed of the two project leaders, the trial statistician, a patient representative, a member of the NAPKON SC, a representative of the Nationale Klinische Studiengruppe (NKSG) Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (ME/CFS) und Post-COVID-19-Syndrom as well as a representative of a recruiting site.</p>
<p id="Par270">The SC was involved in the development of the protocol and ensures transparent management of the trial according to the protocol through recommending and approving modifications as circumstances require. The SC reviews protocol amendments as appropriate. Together with the clinical trial team, the SC will also develop recommendations for publications of trial results including authorship rules. SC Meetings are organized by the CTU UMG.</p>
<p id="Par271">In particular, the SC votes on the further proceedings after the DSMB has made a recommendation on adaptation of the trial.</p></section><section id="Sec56"><h4 class="pmc_sec_title">Statistical Analysis Center</h4>
<p id="Par272">The Statistical Analysis Center (SAC), situated at the University Hospital Göttingen, performs all analyses related to the trial and makes them accessible to the DSMB. The SAC includes the trial statistician.</p></section><section id="Sec57"><h4 class="pmc_sec_title">Patient involvement</h4>
<p id="Par273">A patient representative from Long COVID Germany, a German self-help group, is involved in the planning and conduct of RAPID_REVIVE. She was involved in the early planning process and revised the protocol and informed consent. The patient representative is also part of the steering committee as mentioned above and thus involved in all key decisions regarding the trial. Long COVID Germany also provided advice on how to improve patient recruitment.</p></section></section><section id="Sec58"><h3 class="pmc_sec_title">Composition of the data monitoring committee, its role and reporting structure {21a}</h3>
<p id="Par274">A Data Safety Monitoring Board (DSMB), composed of one statistician and two clinicians from the NUM FOSA (German: Fach- und Organspezifische Arbeitsgruppen, English: area- and organ-specific working groups), was established. One of these was appointed as the chair of the DSMB.</p>
<p id="Par275">The function of the DSMB is to monitor the course of the trial and if necessary to give a recommendation to the sponsor/coordinating investigator/SC for discontinuation, modification, or continuation of the trial. The underlying principles for the DSMB are ethical and safety aspects for the patients. It is the task of the DSMB to examine whether the conduct of the trial is still ethically justifiable, whether security of the patients is ensured, and whether the process of the trial is acceptable. For this the DSMB has to be informed about the adherence to the protocol, the patient recruitment, and the observed adverse events. The DSMB will receive the corresponding reports at the time of the planned interim analyses. The blinded export provided by the data management is used by the trial statistician for the creation of the script for the analysis of the unblinded export. The trial statistician, who is always blinded, gives this code to the independent statistician, who uses it to analyze the unblinded export and transmits the report to the DSMB in encrypted form.</p>
<p id="Par276">Once the pre-specified threshold levels of probability for superiority, inferiority, or equivalence have been reached within a specific APT subprotocol, the Statistical Analyses Center will communicate this event to the DSMB. The DSMB will then review and discuss the reported results. Finally, it will give a recommendation on adaptation of the trial to the SC, which will then vote on the further proceedings. The composition and responsibilities of the DSMB, the structure and procedures of its meetings, and its relationship to other key trial team members (SC), are laid down in an DSMB charter.</p></section><section id="Sec59"><h3 class="pmc_sec_title">Adverse event reporting and harms {22}</h3>
<section id="Sec60"><h4 class="pmc_sec_title">Adverse events</h4>
<p id="Par277">An AE is any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.</p>
<p id="Par278">Over the whole period of patient trial participation, all AEs spontaneously reported by the patient or observed by the investigator must be documented in the medical record and on the designated case report form (AE eCRF page). All AEs must be captured whether regarded as trial related or not.</p>
<p id="Par279">AEs must be described by diagnosis or, if an underlying diagnosis is not known, by symptoms or medically significant laboratory or instrumental abnormalities. The AEs should be documented as described below.</p>
<p id="Par280">Pre-existing conditions are not to be considered an AE, but need to be documented in the medical history section of the eCRF. Worsening of a pre-existing condition is considered an AE and needs to be documented.</p>
<p id="Par281">All AEs, no matter how intense, are to be followed up by the investigator until resolved or judged no longer clinically relevant.</p></section><section id="Sec61"><h4 class="pmc_sec_title">AEs of special interest (AESI)</h4>
<p id="Par282">The following AEs are defined as AESI if these events are different from any pre-existing conditions or a result from known conditions:</p>
<ul class="list" style="list-style-type:disc">
<li><p id="Par283">RBC urine positive (as defined below), at least of moderate intensity</p></li>
<li><p id="Par284">Hematuria (as defined below)</p></li>
<li><p id="Par285">Retroperitoneal colicky pain in connection with suspected or confirmed nephrolithiasis</p></li>
</ul>
<p id="Par286">Severity is a clinical observation and describes the intensity of the event. Because of the lack of widely accepted categorization, the severity of hematuria is classified as follows:</p>
<ul class="list" style="list-style-type:disc">
<li><p id="Par287">Mild: Asymptomatic hematuria; clinical or diagnostic observations only.</p></li>
<li><p id="Par288">Moderate: Symptomatic hematuria, e.g., with moderate flank pain (and including short-term (less than 24 h), standard dose therapy with oral nonsteroidal anti-inflammatory drugs, oral acetaminophen, or oral aspirin), interfering with but not limiting activities of daily living.</p></li>
<li><p id="Par289">Severe: Gross or macrohematuria. Any hematuria with severe flank pain limiting activities of daily living. Any hematuria requiring additional treatment (e.g., oral anti-emetics or muscle relaxants, around-the-clock narcotic analgesics, use of narcotics, or any intravenous treatment) or procedures for maintaining adequate urinary flow (e.g., urinary catheter or bladder irrigation).</p></li>
</ul>
<p id="Par290">The evaluation of RBC in urine will be solely based on findings from microscopic examinations of urinary sediment and not from dipstick reading only. Therefore, all conspicuous dipstick readings will be followed up by a microscopic examination of urinary sediment. All findings of RBC in urine per high-powered field will be listed as urinalysis abnormalities but not as an AE if assessed by the investigator as not clinically significant. The investigator will also assess any increased RBC in urine as not clinically significant if there are more likely alternatives to explain this finding. The following alternative explanations of RBC in urine high will be considered:</p>
<ul class="list" style="list-style-type:disc">
<li><p id="Par291">The urine sample was not properly collected (random midstream clean-catch collection) or evidence of contamination (e.g., presence of bacteria or an unusual number of epithelial cells in urine sediment not explained by other conditions).</p></li>
<li><p id="Par292">Evidence of infection not considered secondary to drug-induced damage.</p></li>
<li><p id="Par293">Likely benign causes, such as menstruation, vigorous exercise, viral illness, trauma, and infection.</p></li>
</ul>
<p id="Par294">If any finding of “RBC in urine high” is assessed by the investigator as clinically significant (causing clinical action, at least retesting), this finding will be reported as the AE “RBC urine positive.”</p>
<p id="Par295">Any occurrence of RBC urine positive will only be defined as the AE “hematuria” if at least one of the following 2 conditions is met:</p>
<ul class="list" style="list-style-type:disc">
<li><p id="Par296">≥ 5 RBCs per high-powered field were found in at least 2 consecutive, properly collected urinalysis specimens and/or</p></li>
<li><p id="Par297">The finding of RBC urine positive had diagnostic or therapeutic consequences.</p></li>
</ul>
<p id="Par298">AESIs will be reported as SAEs as described below.</p></section><section id="Sec62"><h4 class="pmc_sec_title">Documentation of AEs</h4>
<p id="Par299">Adverse events have to be monitored and documented in the eCRF over the whole period of patient trial participation. The following data need to be documented:</p>
<ul class="list" style="list-style-type:disc">
<li><p id="Par300">Characterization of the event (diagnosis; if not available, symptoms)</p></li>
<li><p id="Par301">Onset date/date of resolution</p></li>
<li><p id="Par302">Severity of event (“mild, moderate, severe, life-threatening, fatal”)</p></li>
<li><p id="Par303">Relationship to the IMP (related/not related), the expression “related” means that there is evidence or argument to suggest a reasonable causal relationship between the event and the administration of the IMP, e.g., close temporal connection, exclusion of other causes. The assessment “not related” is appropriate if the AE is clearly or most likely explained by other causes even if a potential relationship between IMP and the AE cannot be completely excluded.</p></li>
<li><p id="Par304">Serious/non-serious</p></li>
<li><p id="Par305">Action taken with regard to IMP (continued/stopped/interrupted)</p></li>
<li><p id="Par306">Outcome of AE</p></li>
</ul></section><section id="Sec63"><h4 class="pmc_sec_title">Pregnancies</h4>
<p id="Par307">In case of pregnancy, the patient must immediately be withdrawn from the trial treatment.</p>
<p id="Par308">Any pregnancy (female trial participant or female partner of male trial participant) that occurs during trial participation must be reported. To ensure patient safety each pregnancy must be reported to CTU Vigilance on the pregnancy reporting form within 24 h of learning of its occurrence. The reporting follows the same instructions as described for SAEs </p>
<p id="Par309">The pregnancy should be followed up to determine outcome, including spontaneous or voluntary termination, details of birth, and the presence/absence of any birth defects, congenital abnormalities, or maternal and new-born complications.</p>
<p id="Par310">The details on the implementation of this requirement is described in a trial specific SAE-manual.</p></section><section id="Sec64"><h4 class="pmc_sec_title">Serious adverse events</h4>
<p id="Par311">A serious adverse event (SAE) is any AE that at any dose.</p>
<ul class="list" style="list-style-type:disc">
<li><p id="Par312">Results in death,</p></li>
<li><p id="Par313">Is life-threatening,</p></li>
<li><p id="Par314">Requires hospitalization or prolongation of existing hospitalization (excluding those for trial therapy and elective or pre-planned treatment/surgery)</p></li>
<li><p id="Par315">Results in persistent or significant disability or incapacity,
</p></li>
<li><p id="Par316">Is a congenital anomaly or birth defect,</p></li>
<li><p id="Par317">Other medically important event: events that may jeopardize the patient or may require an intervention to prevent one of the above characteristics/consequences. Such events should also be considered “serious” in accordance with the definition and have to be reported as SAEs.</p></li>
<li><p id="Par318">Cases of misuse and abuse of IMP should also be reported as SAEs.</p></li>
</ul>
<p id="Par319">Please note:</p>
<ul class="list" style="list-style-type:disc"><li><p id="Par320">The term “life-threatening” in the definition of “serious” refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.</p></li></ul></section><section id="Sec65"><h4 class="pmc_sec_title">Documentation and reporting of SAEs</h4>
<p id="Par321">All SAEs that occur starting from signature of the informed consent form until the end of patient’s follow-up period have to be entered into the eCRF <em>within 24 h</em><em>after investigator awareness</em>. The documented SAEs will be sent to the Sponsor via the reporting function of the eCRF. In case of failure of the electronic reporting function of the eCRF, the SAE paper form must be completed and sent via fax or e-mail <em>within 24 h</em> after investigator awareness to the Vigilance of the CTU UMG.</p>
<p id="Par322">If new information including outcome becomes available or, e.g., relationship to IMP(s) is reconsidered, a SAE follow-up report must be sent within 24 h using the same procedure as for transmitting the initial SAE report. The reporting and processing of the SAEs is described in detail in trial specific SAE-manual.</p></section><section id="Sec66"><h4 class="pmc_sec_title">Specific protocol exceptions to SAE reporting</h4>
<p id="Par323">Events not to be reported as SAEs are hospitalizations for the following:</p>
<ul class="list" style="list-style-type:disc">
<li><p id="Par324">Routine treatment or monitoring of the studied indication, not associated with any deterioration in condition.</p></li>
<li><p id="Par325">Treatment, which was elective or pre-planned, for a pre-existing condition that is unrelated to the indication under study and did not worsen.</p></li>
<li><p id="Par326">Treatment on an emergency, outpatient basis for an event not fulfilling any of the definitions of SAE given above and not resulting in hospital admission.</p></li>
</ul></section></section><section id="Sec67"><h3 class="pmc_sec_title">Frequency and plans for auditing trial conduct {23}</h3>
<p id="Par327">Monitoring and source data verification are the important parts of the auditing trial conduct independent from investigators and the sponsor.</p>
<section id="Sec68"><h4 class="pmc_sec_title">Monitoring</h4>
<p id="Par328">Monitoring is performed by the Clinical Research Associates (CRAs) of UMG CTU. Risk-based monitoring will be done according to ICH-GCP E6 and SOPs to verify that patients’ rights and wellbeing are protected, reported trial data are accurate, complete, and verifiable from source documents and that the trial is conducted in compliance with the currently approved protocol or, if applicable, amendment, with ICH-GCP and with the applicable regulatory.</p>
<p id="Par329">The investigator will accept monitoring visits before, during, and after the clinical trial. Prior to the trial, a site initiation visit at each site OR at an investigators meeting is conducted in order to train and introduce the investigators and their staff to the trial protocol, essential documents, handling of IMP and related trial-specific procedures, ICH-GCP, and national/local regulatory requirements.</p>
<p id="Par330">During the trial, the CRA visits the site regularly OR once a year depending on the recruitment rate and quality of data. During these on-site visits, the CRA verifies that the trial is conducted according to the trial protocol, trial-specific procedures, ICH-GCP, and national/local regulatory requirements. The presence of signed informed consents, eligibility of patients, documentation of primary endpoint, handling of IMP, and documentation/reporting of safety data (e.g., AE/SAE) will be verified by the CRA.</p></section><section id="Sec69"><h4 class="pmc_sec_title">Source data verification (SDV)</h4>
<p id="Par331">The CRA also performs source data verification (SDV) and drug accountability checks to ensure that the clinical trial data which are recorded in the source data and eCRFs are complete and accurate. Extent of source data verification and monitor visit frequency will be adapted for individual sites in case of lack of data quality or a high number of protocol violations. All trial-specific monitoring procedures, monitoring visit frequency, and extent of SDV will be predefined in a trial-specific monitoring manual. The investigator must maintain source documents for each patient in the trial, consisting of case and visit notes (hospital or clinic medical records) containing demographic and medical information, laboratory data, electrocardiograms (ECG), and the results of any other tests or assessments. All information recorded in eCRFs must be traceable to source documents in the patient’s file. The investigator must also keep the original signed informed consent form (a signed copy is given to the patient). The investigator must give the CRA access to all relevant source documents to confirm their consistency with the eCRF entries. Source data as defined by ICH-GCP include original documents, data, and records such as hospital records, clinical and office charts, laboratory notes, memoranda, patients’ diaries or evaluation checklists, pharmacy dispensing records, recorded data from automated instruments, copies or transcriptions certified after verification as being accurate copies, microfiches, photographic negatives, microfilm or magnetic media, X-rays, and records kept at the pharmacy, at the laboratories and at medico-technical departments involved in the clinical trial.</p></section></section><section id="Sec70"><h3 class="pmc_sec_title">Plans for communicating important protocol amendments to relevant parties (e.g., trial participants, ethical committees) {25}</h3>
<p id="Par332">Any change or addition to the protocol can only be made in a written protocol amendment that must be approved by sponsor and the Member State(s). Protocol amendments will be reviewed by the SC as appropriate.</p>
<p id="Par333">Regardless of the need for approval of formal protocol amendments, the investigator is expected to take immediate action required for the safety of any patient included in this trial, even if this action represents a deviation from the protocol. In such cases, the sponsor has to be notified as soon as possible of this action.</p>
<p id="Par334">Information regarding important protocol modifications will be provided in due time to further relevant parties (e.g., ethical committees, nvestigators, trial participants, trial registries, journals).</p></section><section id="Sec71"><h3 class="pmc_sec_title">Dissemination plans {31a}</h3>
<p id="Par335">Upon trial completion the results of this trial will be submitted for publication and/or posted in a publicly accessible database of clinical trial results irrespective of the results of the trial. Reporting guidelines will be taken into account (see <a href="http://www.equator-network.org" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">www.equator-network.org</a>), the Consolidated Standards Of Reporting Trials (CONSORT) statement will be adhered to in the preparation of papers on the results of randomized studies.</p>
<p id="Par336">Each publication of trial results will be in mutual agreement between the coordinating investigator, the other investigators involved, and the CTU/the SC. All data collected in connection with the clinical trial will be treated in confidence by the coordinating investigator and all others involved in the trial, until publication. Interim data and final results may only be published (orally or in writing) with the agreement of the coordinating investigator and the CTU/the SC.</p>
<p id="Par337">To achieve maximum impact of results, different channels of dissemination targeting different stakeholders and communities will be used. Since PCS is a global concern, dissemination of results will not be limited to Germany or Europe. Results of the trial will be published in a scientific peer-reviewed journal under open access conditions. In addition, information on the trial will be disseminated through social media channels and through presentation at national and international conferences of the relevant academic disciplines.</p>
<p id="Par338">All research data collection and generation associated with the trial will follow the guiding principles of findability (F), accessibility (A), interoperability (I), and reusability (R, together: FAIR). To achieve optimum findability, studies will be registered with WHO approved trial registries (F). Data items and forms will be published on the Medical Data Models Portal (MDM Portal, <a href="https://medical-data-models.org" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://medical-data-models.org</a>) (F, A). Where feasible, integration of data and samples into major infrastructures, e.g., the German Biobank Node, the Zentrale Antrags- und Registerstelle (ZARS) and applicable infrastructures of the German Centers for Health Research (Deutsche Zentren der Gesundheitsforschung, DZG) is intended (F, A). Data will be stored in common database and file formats, with comprehensive codebooks explaining file and data format and rules for collection (A, I). Data shall be published under consideration of ethical principles and GDPR regulation and made available with an adequate open license to a broader scientific community (R).</p></section></section><section id="Sec72"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par339">Medical recommendations are based on high-quality evidence, ideally generated by randomized controlled trials (RCTs). Accordingly, to ensure that sufficient data is available to assess a medical situation, a number of RCTs must be conducted in which only a limited number of interventions in a single indication are evaluated. Although this is still the gold standard for gaining clinical-scientific knowledge, it is characterized by high costs, long implementation times and a lack of flexibility with regard to the integration of new findings that are obtained within and outside the respective study. Using the example of acute coronavirus disease 2019 (COVID-19), it became clear that so-called adaptive platform studies offer practicable solutions to the abovementioned problems and are indispensable in a situation in which the evidence base changes continuously and rapidly and study components have to be adapted accordingly. In Germany, the necessary overarching platform is currently being realized by the already BMBF funded NAPKON-TIP project (National Pandemic Cohort Network—Therapeutic Intervention Platform) in close cooperation with the existing structures of NAPKON and NUM (Network of University Medicine).</p>
<p id="Par340">RAPID is the first use case to be assessed using the NAPKON-TIP platform. Despite a large number of considerations regarding treatment options for PCS and a considerable number of studies that have been initiated, very few results from randomized controlled trials are currently available. At the same time, numerous hypotheses concerning potentially effective treatment strategies are slowly emerging from ongoing research [<a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>]. The successful completion of this platform study will add to the very limited evidence base for the treatment of PCS and thus contribute to the health of a large patient population worldwide. In addition to the intervention “antiviral treatment” offered as part of the first ISA RAPID_REVIVE and which is presented in this manuscript in detail, further interventions can be included at a later stage, providing the unique opportunity to compare different interventions in a single trial by responding very quickly to the rapidly changing evidence base for PCS in particular. As part of RAPID_REVIVE patients will also undergo cerebral imaging as well as immunological and virological biomarker assessments. This data will be used to enable stratification of patients with regard to response prediction over the course of the adaptive platform study. If such stratification is feasible, the inclusion and/or exclusion criteria will be adjusted during the study.</p></section><section id="Sec73"><h2 class="pmc_sec_title">Trial status</h2>
<p id="Par341">Protocol version number: V2.0, date: 13.05.2024; date of recruitment begin: 27.08.2024; the approximate date when recruitment will be completed 30.06.2025.</p></section><section id="Sec74"><h2 class="pmc_sec_title">Supplementary Information</h2>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12366011/bin/13063_2025_9008_MOESM1_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">Additional file 1.</a><sup> (1MB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM2"><div class="media p"><div class="caption">
<a href="/articles/instance/12366011/bin/13063_2025_9008_MOESM2_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">Additional file 2.</a><sup> (1MB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="MOESM3"><div class="media p"><div class="caption">
<a href="/articles/instance/12366011/bin/13063_2025_9008_MOESM3_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">Additional file 3.</a><sup> (499KB, pdf) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>This study is funded by the German Federal Ministry of Education and Research (BMBF) Network of University Medicine 2.0: “NUM 2.0", Grant No. 01KX2121, Projects: NAPKON-TIP and NAPKON-TIP: RAPID trial.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<dl class="def-list">
<dt>1MSTST</dt>
<dd><p id="Par6">1-Minute sit-to-stand test</p></dd>
<dt>ACE2</dt>
<dd><p id="Par7">Angiotensin converting enzyme 2 receptor</p></dd>
<dt>AE</dt>
<dd><p id="Par8">Adverse event</p></dd>
<dt>APT</dt>
<dd><p id="Par9">Adaptive Platform Trial</p></dd>
<dt>BCU</dt>
<dd><p id="Par10">Biobanking Core Unit</p></dd>
<dt>BCRP</dt>
<dd><p id="Par11">Breast Cancer Resistance Protein</p></dd>
<dt>BMBF</dt>
<dd><p id="Par12">German Federal Ministry of Education and Research</p></dd>
<dt>CI</dt>
<dd><p id="Par13">Confidence interval</p></dd>
<dt>CYP</dt>
<dd><p id="Par14">Cytochrome</p></dd>
<dt>cMRI</dt>
<dd><p id="Par15">Cerebral magnetic resonance imaging</p></dd>
<dt>CMV</dt>
<dd><p id="Par16">Cytomegalovirus</p></dd>
<dt>CONSORT</dt>
<dd><p id="Par17">Consolidated Standards Of Reporting Trials</p></dd>
<dt>COVID-19</dt>
<dd><p id="Par18">Coronavirus Disease 2019</p></dd>
<dt>CRA</dt>
<dd><p id="Par19">Clinical Research Associate (on-site monitor)</p></dd>
<dt>CTIS</dt>
<dd><p id="Par20">Clinical Trials Information System</p></dd>
<dt>CTU</dt>
<dd><p id="Par21">Clinical trials unit</p></dd>
<dt>DHODH</dt>
<dd><p id="Par22">Dihydroorotate dehydrogenase</p></dd>
<dt>DICOM</dt>
<dd><p id="Par23">Digital Imaging and Communications in Medicine</p></dd>
<dt>DIMA</dt>
<dd><p id="Par24">DICOM Management System</p></dd>
<dt>DMARDs</dt>
<dd><p id="Par25">Disease-modifying anti-rheumatic drugs</p></dd>
<dt>EBV</dt>
<dd><p id="Par26">Epstein-Barr Virus</p></dd>
<dt>ECG</dt>
<dd><p id="Par27">Electrocardiogram</p></dd>
<dt>eCRF</dt>
<dd><p id="Par28">Electronic Case Report Form</p></dd>
<dt>EDC</dt>
<dd><p id="Par29">Electronic Data Capture</p></dd>
<dt>EOS</dt>
<dd><p id="Par30">End of study</p></dd>
<dt>EOT</dt>
<dd><p id="Par31">End of treatment</p></dd>
<dt>FAIR</dt>
<dd><p id="Par32">Findability, Accessibility, Interoperability and Reusability</p></dd>
<dt>FAS</dt>
<dd><p id="Par33">Full Analysis Set</p></dd>
<dt>FSS</dt>
<dd><p id="Par34">Fatigue Severity Scale</p></dd>
<dt>GAD-7</dt>
<dd><p id="Par35">Generalized Anxiety Disorder Scale</p></dd>
<dt>HIV</dt>
<dd><p id="Par36">Human immunodeficiency virus</p></dd>
<dt>HMA</dt>
<dd><p id="Par37">Heads of Medicines Agencies</p></dd>
<dt>IB</dt>
<dd><p id="Par38">Investigator’s Brochure</p></dd>
<dt>ICF</dt>
<dd><p id="Par39">Informed consent form</p></dd>
<dt>ICH-GCP</dt>
<dd><p id="Par40">ICH Topic E6: Guideline for Good Clinical Practice (GCP)</p></dd>
<dt>IMP</dt>
<dd><p id="Par41">Investigational Medicinal Product</p></dd>
<dt>IMU-838</dt>
<dd><p id="Par42">Vidofludimus calcium</p></dd>
<dt>ISA</dt>
<dd><p id="Par43">Intervention-Specific Appendix</p></dd>
<dt>ITT</dt>
<dd><p id="Par44">Intention to treat</p></dd>
<dt>ME/CFS</dt>
<dd><p id="Par45">Chronic fatigue syndrome/myalgic encephalomyelitis</p></dd>
<dt>mMRC</dt>
<dd><p id="Par46">Modified Medical Research Council Dyspnea Scale</p></dd>
<dt>MMRM</dt>
<dd><p id="Par47">Mixed models for repeated measures</p></dd>
<dt>MoCA</dt>
<dd><p id="Par48">Montreal Cognitive Assessment</p></dd>
<dt>MOT</dt>
<dd><p id="Par49">Middle of treatment</p></dd>
<dt>NAPKON</dt>
<dd><p id="Par50">Nationales Pandemie Kohorten Netz</p></dd>
<dt>NUM</dt>
<dd><p id="Par51">Network of University Medicine</p></dd>
<dt>NYHA</dt>
<dd><p id="Par52">New York Heart Association</p></dd>
<dt>PCS</dt>
<dd><p id="Par53">Post COVID syndrome</p></dd>
<dt>PEM</dt>
<dd><p id="Par54">Post exertional malaise</p></dd>
<dt>PHQ</dt>
<dd><p id="Par55">Patient Health Questionnaire</p></dd>
<dt>PI</dt>
<dd><p id="Par56">Principal Investigator</p></dd>
<dt>PP</dt>
<dd><p id="Par57">Per-protocol</p></dd>
<dt>PROM</dt>
<dd><p id="Par58">Patient-reported outcome measures</p></dd>
<dt>PST</dt>
<dd><p id="Par59">Passive standing test</p></dd>
<dt>RBC</dt>
<dd><p id="Par60">Red blood cell count</p></dd>
<dt>S1</dt>
<dd><p id="Par61">Spike 1</p></dd>
<dt>SAE</dt>
<dd><p id="Par62">Serious adverse event</p></dd>
<dt>SAP</dt>
<dd><p id="Par63">Statistical Analysis Plan</p></dd>
<dt>SARS-CoV-2</dt>
<dd><p id="Par64">Severe acute respiratory syndrome coronavirus type 2</p></dd>
<dt>SAC</dt>
<dd><p id="Par65">Statistical Analysis Center</p></dd>
<dt>SC</dt>
<dd><p id="Par66">Steering Committee</p></dd>
<dt>SDV</dt>
<dd><p id="Par67">Source Data Verification</p></dd>
<dt>SF-36-PF</dt>
<dd><p id="Par68">Short Form-36 Physical Function</p></dd>
<dt>SOP </dt>
<dd><p id="Par69">Standard Operating Procedure</p></dd>
<dt>SUSAR</dt>
<dd><p id="Par70">Suspected unexpected serious adverse reaction</p></dd>
<dt>UGT1A1</dt>
<dd><p id="Par71">Uridine-diphosphate glucuronosyltransferase 1A1</p></dd>
<dt>TTP</dt>
<dd><p id="Par72">Trusted Third Party</p></dd>
<dt>ULN</dt>
<dd><p id="Par73">Upper Limit of Normal</p></dd>
<dt>UMG</dt>
<dd><p id="Par74">University Medical Center Göttingen</p></dd>
<dt>UMG CTU</dt>
<dd><p id="Par75">Clinical Trial Unit of the University Medical Center Göttingen</p></dd>
<dt>WHO</dt>
<dd><p id="Par76">World Health Organization</p></dd>
</dl></section><section id="notes1"><h2 class="pmc_sec_title">Authors’ contributions {31b}</h2>
<p>MV is the coordinating investigator; she conceived the study, led the proposal and protocol development. OC is the deputy coordinating investigator, he conceived the study and contributed to protocol development. RGT, RT, TF and SD contributed to protocol development and study conceptualization.TF and SD are the lead trial methodologists. All authors contributed to study design and to development of the proposal. LW and RGT drafted the manuscript, all authors reviewed and approved the final manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding {4}</h2>
<p>Open Access funding enabled and organized by Projekt DEAL. Most aspects of the trial infrastructure are covered by a complementary BMBF grant. The funders do not control the final decision regarding any aspects of the trial: design, conduct, data analysis and interpretation, manuscript writing, and dissemination of trial results.</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability {29}</h2>
<p>Data from the clinical trial will be made available to third parties via the NUM use and access rules. RAPID_REVIVE will obey Annex IV as well as Annex V of the CTR (EU) 536/2014.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar13"><h3 class="pmc_sec_title">Ethics approval and consent to participate {24}</h3>
<p id="Par342">This clinical trial was designed, shall be implemented and reported in accordance with ICH GCP, with applicable regulations (including Regulation (EU) No. 536/2014), and with the ethical principles laid down in the Declaration of Helsinki.</p>
<p id="Par343">This clinical trial protocol has been approved via CTIS by Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) and the central ethics committee of the Trial on 31. May 2024. Prior to randomization, written informed consent will be obtained from the patients.</p></section><section id="FPar14"><h3 class="pmc_sec_title">Consent for publication {32}</h3>
<p id="Par344">The consent forms (2 versions depending on whether an MRI is desired by the patient or not and the consent for secondary use) and other related documentation will be given to participants (Additional files 1, 2 and 3).</p></section><section id="FPar15"><h3 class="pmc_sec_title">Competing interests {28}</h3>
<p id="Par345">OAC reports grants or contracts from BMBF, Cidara, DZIF, EU-DG RTD, F2G, Gilead, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; Consulting fees from Abbvie, AiCuris, Basilea, Biocon, Boston Strategic Partners, Cidara, Seqirus, Gilead, GSK, IQVIA, Janssen, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Mundipharma, Noxxon, Octapharma, Pardes, Partner Therapeutics, Pfizer, PSI, Scynexis, Seres, Shionogi, The Prime Meridian Group, Elion Therapeutics, Menarini, Melinta; Speaker and lecture honoraria from Abbott, Abbvie, Akademie für Infektionsmedizin, Al-Jazeera Pharmaceuticals/Hikma, amedes, AstraZeneca, Deutscher Ärzteverlag, Gilead, GSK, Grupo Biotoscana/United Medical/Knight, Ipsen Pharma, Medscape/WebMD, MedUpdate, MSD, Moderna, Mundipharma, Noscendo, Paul-Martini-Stiftung, Pfizer, Sandoz, Seqirus, Shionogi, streamedup!, Touch Independent, Vitis; Payment for expert testimony Cidara; Participation on a DRC, DSMB, DMC, Advisory Board for Cidara, IQVIA, Janssen, MedPace, PSI, Pulmocide, Vedanta Biosciences, AstraZeneca, Melinta. </p>
<p id="Par346"> MV reports grants or contracts from MSD, Heel, BioNTech, Roche, SD Biosensor, Tillotts; Consulting fees from Ferring, Tillotts, Bioaster; Speaker and lecture honoraria from Akademie für Ärztliche Fort- und Weiterbildung, Akadmie für Infektionsmedizin, Astra Zeneca, bioMerieux, DGI, EUMEDICA, European Society of Neurogastroenterology, Ferring, FomF GmbH, Förderkreis Malteser, Frankfurter Bürger Universität, GILEAD, GSK, Helios Kliniken, Hessisches Landessozialgericht, Janssen Cilag GmbH, Jörg Eikerle Beratung, Klinikum Leverkusen, Lahn-Dill Kliniken, Landesärztekammer Hessen, LMU Kliniken, Med. Gesellschaft Bad Homburg, MSD, Pfizer, St. Vincent Hospital, Tillotts. The other authors declare that they have no competing interests.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher’s Note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Chen T, Song J, Liu H, Zheng H, Chen C. Positive Epstein-Barr virus detection in coronavirus disease 2019 (COVID-19) patients. Sci Rep. 2021;11:10902. 10.1038/s41598-021-90351-y.
</cite> [<a href="https://doi.org/10.1038/s41598-021-90351-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8149409/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34035353/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20T,%20Song%20J,%20Liu%20H,%20Zheng%20H,%20Chen%20C.%20Positive%20Epstein-Barr%20virus%20detection%20in%20coronavirus%20disease%202019%20(COVID-19)%20patients.%20Sci%20Rep.%202021;11:10902.%2010.1038/s41598-021-90351-y." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Augustin M, Schommers P, Stecher M, Dewald F, Gieselmann L, Gruell H, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. Lancet Reg Health Eur. 2021;6: 100122. 10.1016/j.lanepe.2021.100122.
</cite> [<a href="https://doi.org/10.1016/j.lanepe.2021.100122" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8129613/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34027514/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Augustin%20M,%20Schommers%20P,%20Stecher%20M,%20Dewald%20F,%20Gieselmann%20L,%20Gruell%20H,%20et%20al.%20Post-COVID%20syndrome%20in%20non-hospitalised%20patients%20with%20COVID-19:%20a%20longitudinal%20prospective%20cohort%20study.%20Lancet%20Reg%20Health%20Eur.%202021;6:%20100122.%2010.1016/j.lanepe.2021.100122." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601–15. 10.1038/s41591-021-01283-z.
</cite> [<a href="https://doi.org/10.1038/s41591-021-01283-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8893149/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33753937/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nalbandian%20A,%20Sehgal%20K,%20Gupta%20A,%20Madhavan%20MV,%20McGroder%20C,%20Stevens%20JS,%20et%20al.%20Post-acute%20COVID-19%20syndrome.%20Nat%20Med.%202021;27:601%E2%80%9315.%2010.1038/s41591-021-01283-z." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23:194–202. 10.1038/s41590-021-01104-y.
</cite> [<a href="https://doi.org/10.1038/s41590-021-01104-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9127978/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35105985/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mehandru%20S,%20Merad%20M.%20Pathological%20sequelae%20of%20long-haul%20COVID.%20Nat%20Immunol.%202022;23:194%E2%80%93202.%2010.1038/s41590-021-01104-y." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626–31. 10.1038/s41591-021-01292-y.
</cite> [<a href="https://doi.org/10.1038/s41591-021-01292-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7611399/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33692530/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sudre%20CH,%20Murray%20B,%20Varsavsky%20T,%20Graham%20MS,%20Penfold%20RS,%20Bowyer%20RC,%20et%20al.%20Attributes%20and%20predictors%20of%20long%20COVID.%20Nat%20Med.%202021;27:626%E2%80%9331.%2010.1038/s41591-021-01292-y." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Rajan S, Khunti K, Alwan N, Steves C, MacDermott N, Morsella A, et al. In the wake of the pandemic: Preparing for Long COVID. Copenhagen (Denmark); 2021.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/33877759/" class="usa-link">PubMed</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Parums DV. Editorial: Long COVID, or post-COVID syndrome, and the global impact on health care. Med Sci Monit. 2021;27: e933446. 10.12659/MSM.933446.
</cite> [<a href="https://doi.org/10.12659/MSM.933446" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8194290/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34092779/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Parums%20DV.%20Editorial:%20Long%20COVID,%20or%20post-COVID%20syndrome,%20and%20the%20global%20impact%20on%20health%20care.%20Med%20Sci%20Monit.%202021;27:%20e933446.%2010.12659/MSM.933446." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203:631–7. 10.1002/path.1570.</cite> [<a href="https://doi.org/10.1002/path.1570" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7167720/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15141377/" class="usa-link">PubMed</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Chen M, Shen W, Rowan NR, Kulaga H, Hillel A, Ramanathan M, Lane AP. Elevated ACE-2 expression in the olfactory neuroepithelium: implications for anosmia and upper respiratory SARS-CoV-2 entry and replication. Eur Respir J. 2020. 10.1183/13993003.01948-2020.
</cite> [<a href="https://doi.org/10.1183/13993003.01948-2020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7439429/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32817004/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20M,%20Shen%20W,%20Rowan%20NR,%20Kulaga%20H,%20Hillel%20A,%20Ramanathan%20M,%20Lane%20AP.%20Elevated%20ACE-2%20expression%20in%20the%20olfactory%20neuroepithelium:%20implications%20for%20anosmia%20and%20upper%20respiratory%20SARS-CoV-2%20entry%20and%20replication.%20Eur%20Respir%20J.%202020.%2010.1183/13993003.01948-2020." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324:603–5. 10.1001/jama.2020.12603.
</cite> [<a href="https://doi.org/10.1001/jama.2020.12603" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7349096/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32644129/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Carf%C3%AC%20A,%20Bernabei%20R,%20Landi%20F.%20Persistent%20symptoms%20in%20patients%20after%20acute%20COVID-19.%20JAMA.%202020;324:603%E2%80%935.%2010.1001/jama.2020.12603." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398:747–58. 10.1016/S0140-6736(21)01755-4.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(21)01755-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8389999/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34454673/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Huang%20L,%20Yao%20Q,%20Gu%20X,%20Wang%20Q,%20Ren%20L,%20Wang%20Y,%20et%20al.%201-year%20outcomes%20in%20hospital%20survivors%20with%20COVID-19:%20a%20longitudinal%20cohort%20study.%20Lancet.%202021;398:747%E2%80%9358.%2010.1016/S0140-6736(21)01755-4." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, Villapol S. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11:16144. 10.1038/s41598-021-95565-8.
</cite> [<a href="https://doi.org/10.1038/s41598-021-95565-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8352980/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34373540/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lopez-Leon%20S,%20Wegman-Ostrosky%20T,%20Perelman%20C,%20Sepulveda%20R,%20Rebolledo%20PA,%20Cuapio%20A,%20Villapol%20S.%20More%20than%2050%20long-term%20effects%20of%20COVID-19:%20a%20systematic%20review%20and%20meta-analysis.%20Sci%20Rep.%202021;11:16144.%2010.1038/s41598-021-95565-8." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re’em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38: 101019. 10.1016/j.eclinm.2021.101019.
</cite> [<a href="https://doi.org/10.1016/j.eclinm.2021.101019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8280690/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34308300/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Davis%20HE,%20Assaf%20GS,%20McCorkell%20L,%20Wei%20H,%20Low%20RJ,%20Re%E2%80%99em%20Y,%20et%20al.%20Characterizing%20long%20COVID%20in%20an%20international%20cohort:%207%20months%20of%20symptoms%20and%20their%20impact.%20EClinicalMedicine.%202021;38:%20101019.%2010.1016/j.eclinm.2021.101019." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21:133–46. 10.1038/s41579-022-00846-2.
</cite> [<a href="https://doi.org/10.1038/s41579-022-00846-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9839201/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36639608/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Davis%20HE,%20McCorkell%20L,%20Vogel%20JM,%20Topol%20EJ.%20Long%20COVID:%20major%20findings,%20mechanisms%20and%20recommendations.%20Nat%20Rev%20Microbiol.%202023;21:133%E2%80%9346.%2010.1038/s41579-022-00846-2." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022;54:1473–87. 10.1080/07853890.2022.2076901.</cite> [<a href="https://doi.org/10.1080/07853890.2022.2076901" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9132392/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35594336/" class="usa-link">PubMed</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Patterson BK, Francisco EB, Yogendra R, Long E, Pise A, Rodrigues H, et al. Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection. Front Immunol. 2021;12: 746021. 10.3389/fimmu.2021.746021.
</cite> [<a href="https://doi.org/10.3389/fimmu.2021.746021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8784688/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35082777/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Patterson%20BK,%20Francisco%20EB,%20Yogendra%20R,%20Long%20E,%20Pise%20A,%20Rodrigues%20H,%20et%20al.%20Persistence%20of%20SARS%20CoV-2%20S1%20protein%20in%20CD16+%20monocytes%20in%20post-acute%20sequelae%20of%20COVID-19%20(PASC)%20up%20to%2015%20months%20post-infection.%20Front%20Immunol.%202021;12:%20746021.%2010.3389/fimmu.2021.746021." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. bioRxiv. 2021. 10.1101/2020.11.03.367391.
</cite> [<a href="https://doi.org/10.1038/s41586-021-03207-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8221082/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33461210/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gaebler%20C,%20Wang%20Z,%20Lorenzi%20JCC,%20Muecksch%20F,%20Finkin%20S,%20Tokuyama%20M,%20et%20al.%20Evolution%20of%20antibody%20immunity%20to%20SARS-CoV-2.%20bioRxiv.%202021.%2010.1101/2020.11.03.367391." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Zollner A, Koch R, Jukic A, Pfister A, Meyer M, Rössler A, et al. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology. 2022;163:495-506.e8. 10.1053/j.gastro.2022.04.037.
</cite> [<a href="https://doi.org/10.1053/j.gastro.2022.04.037" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9057012/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35508284/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zollner%20A,%20Koch%20R,%20Jukic%20A,%20Pfister%20A,%20Meyer%20M,%20R%C3%B6ssler%20A,%20et%20al.%20Postacute%20COVID-19%20is%20characterized%20by%20gut%20viral%20antigen%20persistence%20in%20inflammatory%20bowel%20diseases.%20Gastroenterology.%202022;163:495-506.e8.%2010.1053/j.gastro.2022.04.037." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med. 2023;183:554–64. 10.1001/jamainternmed.2023.0743.
</cite> [<a href="https://doi.org/10.1001/jamainternmed.2023.0743" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10037200/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36951829/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xie%20Y,%20Choi%20T,%20Al-Aly%20Z.%20Association%20of%20treatment%20with%20nirmatrelvir%20and%20the%20risk%20of%20post-COVID-19%20condition.%20JAMA%20Intern%20Med.%202023;183:554%E2%80%9364.%2010.1001/jamainternmed.2023.0743." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Vehreschild MJGT, Atanasov P, Yurko K, Oancea C, Popov G, Smesnoi V, et al. Safety and efficacy of Vidofludimus calcium in patients hospitalized with COVID-19: a double-blind, randomized, placebo-controlled, phase 2 trial. Infect Dis Ther. 2022;11:2159–76. 10.1007/s40121-022-00690-0.
</cite> [<a href="https://doi.org/10.1007/s40121-022-00690-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9568890/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36242741/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vehreschild%20MJGT,%20Atanasov%20P,%20Yurko%20K,%20Oancea%20C,%20Popov%20G,%20Smesnoi%20V,%20et%20al.%20Safety%20and%20efficacy%20of%20Vidofludimus%20calcium%20in%20patients%20hospitalized%20with%20COVID-19:%20a%20double-blind,%20randomized,%20placebo-controlled,%20phase%202%20trial.%20Infect%20Dis%20Ther.%202022;11:2159%E2%80%9376.%2010.1007/s40121-022-00690-0." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Geng LN, Bonilla HF, Shafer RW, Miglis MG, Yang PC. The use of Nirmatrelvir-ritonavir in a case of breakthrough long COVID. Explor Res Hypothes Med. 2023;000:394–6. 10.14218/ERHM.2022.00045.</cite> [<a href="https://scholar.google.com/scholar_lookup?Geng%20LN,%20Bonilla%20HF,%20Shafer%20RW,%20Miglis%20MG,%20Yang%20PC.%20The%20use%20of%20Nirmatrelvir-ritonavir%20in%20a%20case%20of%20breakthrough%20long%20COVID.%20Explor%20Res%20Hypothes%20Med.%202023;000:394%E2%80%936.%2010.14218/ERHM.2022.00045." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Peluso MJ, Deveau T-M, Munter SE, Ryder D, Buck A, Beck-Engeser G, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest. 2023. 10.1172/JCI163669.
</cite> [<a href="https://doi.org/10.1172/JCI163669" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9888380/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36454631/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Peluso%20MJ,%20Deveau%20T-M,%20Munter%20SE,%20Ryder%20D,%20Buck%20A,%20Beck-Engeser%20G,%20et%20al.%20Chronic%20viral%20coinfections%20differentially%20affect%20the%20likelihood%20of%20developing%20long%20COVID.%20J%20Clin%20Invest.%202023.%2010.1172/JCI163669." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barr virus reactivation. Pathogens. 2021. 10.3390/pathogens10060763.
</cite> [<a href="https://doi.org/10.3390/pathogens10060763" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8233978/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34204243/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gold%20JE,%20Okyay%20RA,%20Licht%20WE,%20Hurley%20DJ.%20Investigation%20of%20long%20COVID%20prevalence%20and%20its%20relationship%20to%20Epstein-Barr%20virus%20reactivation.%20Pathogens.%202021.%2010.3390/pathogens10060763." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Lehner GF, Klein SJ, Zoller H, Peer A, Bellmann R, Joannidis M. Correlation of interleukin-6 with Epstein-Barr virus levels in COVID-19. Crit Care. 2020;24:657. 10.1186/s13054-020-03384-6.
</cite> [<a href="https://doi.org/10.1186/s13054-020-03384-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7682685/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33228750/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lehner%20GF,%20Klein%20SJ,%20Zoller%20H,%20Peer%20A,%20Bellmann%20R,%20Joannidis%20M.%20Correlation%20of%20interleukin-6%20with%20Epstein-Barr%20virus%20levels%20in%20COVID-19.%20Crit%20Care.%202020;24:657.%2010.1186/s13054-020-03384-6." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Rohrhofer J, Graninger M, Lettenmaier L, Schweighardt J, Gentile SA, Koidl L, et al. Association between Epstein-Barr-virus reactivation and development of long-COVID fatigue. Allergy. 2023;78:297–9. 10.1111/all.15471.
</cite> [<a href="https://doi.org/10.1111/all.15471" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9538037/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35950630/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rohrhofer%20J,%20Graninger%20M,%20Lettenmaier%20L,%20Schweighardt%20J,%20Gentile%20SA,%20Koidl%20L,%20et%20al.%20Association%20between%20Epstein-Barr-virus%20reactivation%20and%20development%20of%20long-COVID%20fatigue.%20Allergy.%202023;78:297%E2%80%939.%2010.1111/all.15471." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Paolucci S, Cassaniti I, Novazzi F, Fiorina L, Piralla A, Comolli G, et al. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. Int J Infect Dis. 2021;104:315–9. 10.1016/j.ijid.2020.12.051.
</cite> [<a href="https://doi.org/10.1016/j.ijid.2020.12.051" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7833117/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33359064/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Paolucci%20S,%20Cassaniti%20I,%20Novazzi%20F,%20Fiorina%20L,%20Piralla%20A,%20Comolli%20G,%20et%20al.%20EBV%20DNA%20increase%20in%20COVID-19%20patients%20with%20impaired%20lymphocyte%20subpopulation%20count.%20Int%20J%20Infect%20Dis.%202021;104:315%E2%80%939.%2010.1016/j.ijid.2020.12.051." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Muehler A, Peelen E, Kohlhof H, Gröppel M, Vitt D. Vidofludimus calcium, a next generation DHODH inhibitor for the treatment of relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020;43: 102129. 10.1016/j.msard.2020.102129.
</cite> [<a href="https://doi.org/10.1016/j.msard.2020.102129" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32428844/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Muehler%20A,%20Peelen%20E,%20Kohlhof%20H,%20Gr%C3%B6ppel%20M,%20Vitt%20D.%20Vidofludimus%20calcium,%20a%20next%20generation%20DHODH%20inhibitor%20for%20the%20treatment%20of%20relapsing-remitting%20multiple%20sclerosis.%20Mult%20Scler%20Relat%20Disord.%202020;43:%20102129.%2010.1016/j.msard.2020.102129." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Hahn F, Wangen C, Häge S, Peter AS, Dobler G, Hurst B, et al. IMU-838, a developmental DHODH inhibitor in phase II for autoimmune disease, shows anti-SARS-CoV-2 and broad-spectrum antiviral efficacy <em>in vitro</em>. Viruses. 2020. 10.3390/v12121394.</cite> [<a href="https://doi.org/10.3390/v12121394" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7762174/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33291455/" class="usa-link">PubMed</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Bell DS. The doctor's guide to chronic fatigue syndrome : understanding, treating, and living with CFIDS / David S. Bell. Reading, Mass.: Addison-Wesley Pub. Co; 1994.</cite>
</li>
<li id="CR30">
<span class="label">30.</span><cite>sarram. 14.6. 2020_09_HMA_CTFG_Contraception_guidance_Version_1.2 draft.</cite>
</li>
<li id="CR31">
<span class="label">31.</span><cite>Shahid A, Wilkinson K, Marcu S, Shapiro CM. Fatigue Severity Scale (FSS) 2011: Springer New York. 10.1007/978-1-4419-9893-4_35.</cite>
</li>
<li id="CR32">
<span class="label">32.</span><cite>Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092–7. 10.1001/archinte.166.10.1092.
</cite> [<a href="https://doi.org/10.1001/archinte.166.10.1092" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16717171/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Spitzer%20RL,%20Kroenke%20K,%20Williams%20JBW,%20L%C3%B6we%20B.%20A%20brief%20measure%20for%20assessing%20generalized%20anxiety%20disorder:%20the%20GAD-7.%20Arch%20Intern%20Med.%202006;166:1092%E2%80%937.%2010.1001/archinte.166.10.1092." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Kroenke K, Strine TW, Spitzer RL, Williams JBW, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114:163–73. 10.1016/j.jad.2008.06.026.
</cite> [<a href="https://doi.org/10.1016/j.jad.2008.06.026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18752852/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kroenke%20K,%20Strine%20TW,%20Spitzer%20RL,%20Williams%20JBW,%20Berry%20JT,%20Mokdad%20AH.%20The%20PHQ-8%20as%20a%20measure%20of%20current%20depression%20in%20the%20general%20population.%20J%20Affect%20Disord.%202009;114:163%E2%80%9373.%2010.1016/j.jad.2008.06.026." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med. 2002;64:258–66. 10.1097/00006842-200203000-00008.
</cite> [<a href="https://doi.org/10.1097/00006842-200203000-00008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11914441/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kroenke%20K,%20Spitzer%20RL,%20Williams%20JBW.%20The%20PHQ-15:%20validity%20of%20a%20new%20measure%20for%20evaluating%20the%20severity%20of%20somatic%20symptoms.%20Psychosom%20Med.%202002;64:258%E2%80%9366.%2010.1097/00006842-200203000-00008." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Gräfe K, Zipfel S, Herzog W, Löwe B. Screening psychischer Störungen mit dem“Gesundheitsfragebogen für Patienten (PHQ-D). Diagnostica. 2004. 10.1026/0012-1924.50.4.171.</cite> [<a href="https://scholar.google.com/scholar_lookup?Gr%C3%A4fe%20K,%20Zipfel%20S,%20Herzog%20W,%20L%C3%B6we%20B.%20Screening%20psychischer%20St%C3%B6rungen%20mit%20dem%E2%80%9CGesundheitsfragebogen%20f%C3%BCr%20Patienten%20(PHQ-D).%20Diagnostica.%202004.%2010.1026/0012-1924.50.4.171." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Vestbo J, Hurd SS, Rodriguez-Roisin R. The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD)–why and what? Clin Respir J. 2012;6:208–14. 10.1111/crj.12002.
</cite> [<a href="https://doi.org/10.1111/crj.12002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22906068/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Vestbo%20J,%20Hurd%20SS,%20Rodriguez-Roisin%20R.%20The%202011%20revision%20of%20the%20global%20strategy%20for%20the%20diagnosis,%20management%20and%20prevention%20of%20COPD%20(GOLD)%E2%80%93why%20and%20what?%20Clin%20Respir%20J.%202012;6:208%E2%80%9314.%2010.1111/crj.12002." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Cotler J, Holtzman C, Dudun C, Jason LA. A brief questionnaire to assess post-exertional malaise. Diagnostics (Basel). 2018. 10.3390/diagnostics8030066.
</cite> [<a href="https://doi.org/10.3390/diagnostics8030066" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6165517/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30208578/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cotler%20J,%20Holtzman%20C,%20Dudun%20C,%20Jason%20LA.%20A%20brief%20questionnaire%20to%20assess%20post-exertional%20malaise.%20Diagnostics%20(Basel).%202018.%2010.3390/diagnostics8030066." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–9. 10.1111/j.1532-5415.2005.53221.x.
</cite> [<a href="https://doi.org/10.1111/j.1532-5415.2005.53221.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15817019/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nasreddine%20ZS,%20Phillips%20NA,%20B%C3%A9dirian%20V,%20Charbonneau%20S,%20Whitehead%20V,%20Collin%20I,%20et%20al.%20The%20Montreal%20cognitive%20assessment,%20MoCA:%20a%20brief%20screening%20tool%20for%20mild%20cognitive%20impairment.%20J%20Am%20Geriatr%20Soc.%202005;53:695%E2%80%939.%2010.1111/j.1532-5415.2005.53221.x." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Roma M, Marden CL, Rowe PC. Passive standing tests for the office diagnosis of postural tachycardia syndrome: new methodological considerations. Fatigue Biomed Health Behav. 2018;6:179–92. 10.1080/21641846.2018.1512836.</cite> [<a href="https://scholar.google.com/scholar_lookup?Roma%20M,%20Marden%20CL,%20Rowe%20PC.%20Passive%20standing%20tests%20for%20the%20office%20diagnosis%20of%20postural%20tachycardia%20syndrome:%20new%20methodological%20considerations.%20Fatigue%20Biomed%20Health%20Behav.%202018;6:179%E2%80%9392.%2010.1080/21641846.2018.1512836." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Melfi VF, Page C. Estimation after adaptive allocation. J Stat Plann Inference. 2000;87:353–63. 10.1016/S0378-3758(99)00198-6.</cite> [<a href="https://scholar.google.com/scholar_lookup?Melfi%20VF,%20Page%20C.%20Estimation%20after%20adaptive%20allocation.%20J%20Stat%20Plann%20Inference.%202000;87:353%E2%80%9363.%2010.1016/S0378-3758(99)00198-6." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Röver C, Friede T. Dynamically borrowing strength from another study through shrinkage estimation. Stat Methods Med Res. 2020;29:293–308. 10.1177/0962280219833079.
</cite> [<a href="https://doi.org/10.1177/0962280219833079" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30821201/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?R%C3%B6ver%20C,%20Friede%20T.%20Dynamically%20borrowing%20strength%20from%20another%20study%20through%20shrinkage%20estimation.%20Stat%20Methods%20Med%20Res.%202020;29:293%E2%80%93308.%2010.1177/0962280219833079." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Mütze T, Friede T. Data monitoring committees for clinical trials evaluating treatments of COVID-19. Contemp Clin Trials. 2020;98: 106154. 10.1016/j.cct.2020.106154.
</cite> [<a href="https://doi.org/10.1016/j.cct.2020.106154" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7833551/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32961361/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?M%C3%BCtze%20T,%20Friede%20T.%20Data%20monitoring%20committees%20for%20clinical%20trials%20evaluating%20treatments%20of%20COVID-19.%20Contemp%20Clin%20Trials.%202020;98:%20106154.%2010.1016/j.cct.2020.106154." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366011/bin/13063_2025_9008_MOESM1_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">Additional file 1.</a><sup> (1MB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366011/bin/13063_2025_9008_MOESM2_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">Additional file 2.</a><sup> (1MB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material3_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12366011/bin/13063_2025_9008_MOESM3_ESM.pdf" data-ga-action="click_feat_suppl" class="usa-link">Additional file 3.</a><sup> (499KB, pdf) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>Data from the clinical trial will be made available to third parties via the NUM use and access rules. RAPID_REVIVE will obey Annex IV as well as Annex V of the CTR (EU) 536/2014.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Trials are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s13063-025-09008-0"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/13063_2025_Article_9008.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.5 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12366011/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12366011/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12366011%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12366011/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12366011/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12366011/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40830806/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12366011/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40830806/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12366011/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12366011/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="wDLlTBGZLlYsRDOeXhIjFiZ4NxFTlTtMuBvzNRwybNSJHtLZMmAw8B2kz4NT0Qje">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
